

Classification and diagnosis of myeloproliferative neopl Organization criteria and point-of-care diagnostic algor

Leukemia

22, 14-22

DOI: [10.1038/sj.leu.2404955](https://doi.org/10.1038/sj.leu.2404955)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 2 | Primary eosinophilic disorders: A concise review. <i>Current Hematologic Malignancy Reports</i> , 2008, 3, 37-43. | 1.2 | 8 |
| 3 | Systemic mastocytosis with acute myelomonocytic leukemia: a case report. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2008, 24, 182-185. | 0.3 | 1 |
| 5 | Advanced mast cell disease: an Italian Hematological Multicenter experience. <i>International Journal of Hematology</i> , 2008, 88, 483-488. | 0.7 | 44 |
| 7 | The presence of <i>JAK2</i> V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. <i>American Journal of Hematology</i> , 2008, 83, 363-365. | 2.0 | 37 |
| 8 | Essential thrombocythemia, polycythemia vera, and myelofibrosis: Current management and the prospect of targeted therapy. <i>American Journal of Hematology</i> , 2008, 83, 491-497. | 2.0 | 80 |
| 9 | Tel/PDGFR β inhibits self-renewal and directs myelomonocytic differentiation of ES cells. <i>Leukemia Research</i> , 2008, 32, 1554-1564. | 0.4 | 7 |
| 10 | Gene expression profiling distinguishes <i>JAK2</i> V617F-negative from <i>JAK2</i> V617F-positive patients in essential thrombocythemia. <i>Leukemia</i> , 2008, 22, 1368-1376. | 3.3 | 34 |
| 11 | Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. <i>Leukemia</i> , 2008, 22, 1335-1342. | 3.3 | 118 |
| 12 | Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. <i>Leukemia</i> , 2008, 22, 1494-1502. | 3.3 | 102 |
| 13 | Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs). <i>Leukemia</i> , 2008, 22, 1818-1827. | 3.3 | 31 |
| 14 | BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features. <i>Leukemia</i> , 2008, 22, 1975-1989. | 3.3 | 21 |
| 15 | Bortezomib therapy in myelofibrosis: a phase II clinical trial. <i>Leukemia</i> , 2008, 22, 1636-1638. | 3.3 | 33 |
| 16 | Identification of marker genes including <i>RUNX3</i> (<i>AML2</i>) that discriminate between different myeloproliferative neoplasms and normal individuals. <i>Leukemia</i> , 2008, 22, 1773-1778. | 3.3 | 9 |
| 17 | The WHO 2008 classification of Ph-myeloproliferative disorders: statement of the Czech MPD Working Group. <i>Leukemia</i> , 2008, 22, 2118-2119. | 3.3 | 6 |
| 18 | Low <i>JAK2</i> V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. <i>Leukemia</i> , 2008, 22, 756-761. | 3.3 | 254 |
| 19 | 8p11 myeloproliferative syndrome preceded by t(8;9)(p11;q33), CEP110/FGFR1 fusion transcript: morphologic, molecular, and cytogenetic characterization of myeloid neoplasms associated with eosinophilia and FGFR1 abnormality. <i>Cancer Genetics and Cytogenetics</i> , 2008, 181, 93-99. | 1.0 | 24 |
| 20 | Single-Cell Profiling Identifies Aberrant STAT5 Activation in Myeloid Malignancies with Specific Clinical and Biologic Correlates. <i>Cancer Cell</i> , 2008, 14, 335-343. | 7.7 | 219 |
| 21 | The impact of <i>JAK2</i> and <i>MPL</i> mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. <i>Blood</i> , 2008, 111, 4922-4929. | 0.6 | 319 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 22 | <i>JAK</i> and <i>MPL</i> mutations in myeloid malignancies. <i>Leukemia and Lymphoma</i> , 2008, 49, 388-397. | 0.6 | 77 |
| 24 | The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. <i>Blood</i> , 2008, 112, 231-239. | 0.6 | 158 |
| 25 | Malleable Immunoglobulin Genes and Hematopathology – The Good, the Bad, and the Ugly. <i>Journal of Molecular Diagnostics</i> , 2008, 10, 396-410. | 1.2 | 13 |
| 26 | JAK2V617F Mutation Screening as Part of the Hypercoagulable Work-up in the Absence of Splanchnic Venous Thrombosis or Overt Myeloproliferative Neoplasm: Assessment of Value in a Series of 664 Consecutive Patients. <i>Mayo Clinic Proceedings</i> , 2008, 83, 457-459. | 1.4 | 47 |
| 27 | Pharmacotherapy of essential thrombocythemia. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1679-1685. | 0.9 | 1 |
| 28 | Epigenetic alterations and anti-epigenetic therapy in myelofibrosis. <i>Leukemia and Lymphoma</i> , 2008, 49, 2231-2232. | 0.6 | 2 |
| 29 | Eosinophilia With <i>FIP1L1-PDGFR</i> Fusion in a Patient With Chronic Myelomonocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 2040-2041. | 0.8 | 11 |
| 30 | Mutant Molecules of Interest in Myeloproliferative Neoplasms: Introduction. <i>Acta Haematologica</i> , 2008, 119, 192-193. | 0.7 | 7 |
| 31 | <i>KIT</i> and Mastocytosis. <i>Acta Haematologica</i> , 2008, 119, 194-198. | 0.7 | 33 |
| 32 | Severe Eosinophilia as a Manifestation of Acute Graft-versus-Host Disease. <i>Oncology</i> , 2008, 75, 134-136. | 0.9 | 7 |
| 33 | Validation of the revised 2008 WHO diagnostic criteria in 75 suspected cases of myeloproliferative neoplasm. <i>Leukemia and Lymphoma</i> , 2008, 49, 1784-1791. | 0.6 | 6 |
| 34 | Isolated Erythrocythemia: A Distinct Entity or a Sub-type of Polycythemia Vera?. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 230-232. | 0.6 | 1 |
| 35 | Therapeutic options for patients with clonal and idiopathic hypereosinophilia. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1039-1050. | 1.9 | 7 |
| 36 | GATA1 is overexpressed in patients with essential thrombocythemia and polycythemia vera but not in patients with primary myelofibrosis or chronic myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 1416-1419. | 0.6 | 14 |
| 37 | Chronic myelomonocytic leukemia with antecedent refractory anemia with excess blasts: Further evidence for the arbitrary nature of current classification systems. <i>Leukemia and Lymphoma</i> , 2008, 49, 1292-1296. | 0.6 | 10 |
| 38 | Is chronic myelomonocytic leukemia more akin to myelodysplastic or myeloproliferative neoplasms and does it matter?. <i>Leukemia and Lymphoma</i> , 2008, 49, 1225-1227. | 0.6 | 2 |
| 39 | Idiopathic erythrocytosis: a non-entity?. <i>Leukemia and Lymphoma</i> , 2008, 49, 1649-1650. | 0.6 | 1 |
| 40 | The rare t(6;8) (q27;p11) translocation in a case of chronic myeloid neoplasm mimicking polycythemia vera. <i>Leukemia and Lymphoma</i> , 2008, 49, 1832-1835. | 0.6 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 41 | Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy. <i>Haematologica</i> , 2008, 93, 1723-1727. | 1.7 | 41 |
| 42 | New Advances in the Pathogenesis and Therapy of Essential Thrombocythemia. Hematology American Society of Hematology Education Program, 2008, 2008, 76-82. | 0.9 | 12 |
| 43 | Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24%577 first-degree relatives of 11%039 patients with myeloproliferative neoplasms in Sweden. <i>Blood</i> , 2008, 112, 2199-2204. | 0.6 | 226 |
| 44 | How we diagnose and treat WHO-defined systemic mastocytosis in adults. <i>Haematologica</i> , 2008, 93, 6-9. | 1.7 | 23 |
| 45 | An update of molecular pathogenesis and diagnosis of myeloproliferative disorders in the JAK2 era. <i>Chinese Medical Journal</i> , 2008, 121, 1838-1842. | 0.9 | 0 |
| 46 | Clinical Performance of <i>JAK2</i> V617F Mutation Detection Assays in a Molecular Diagnostics Laboratory. <i>American Journal of Clinical Pathology</i> , 2009, 132, 713-721. | 0.4 | 41 |
| 47 | Philadelphia Chromosome-Negative Chronic Myeloproliferative Disease. <i>American Journal of Clinical Pathology</i> , 2009, 132, 261-280. | 0.4 | 33 |
| 48 | JAK2 V617F MUTATION AND PRV-1 OVEREXPRESSION: RELEVANCE IN THE DIAGNOSIS OF POLYCYTHAEMIA VERA AND ESSENTIAL THROMBOCYTHAEMIA. <i>Acta Clinica Belgica</i> , 2009, 64, 429-433. | 0.5 | 2 |
| 49 | Allogeneic hematopoietic cell transplantation for patients with myelofibrosis. <i>Current Opinion in Hematology</i> , 2009, 16, 140-146. | 1.2 | 14 |
| 50 | A novel Janus Kinase 2 mutation involving 14th intron splicing region in a patient with essential thrombocythemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 2089-2091. | 0.6 | 0 |
| 51 | Inhibition of G1 to S Phase Progression by a Novel Zinc Finger Protein P58TFL at P-bodies. <i>Molecular Cancer Research</i> , 2009, 7, 880-889. | 1.5 | 24 |
| 52 | Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 215-237. | 1.6 | 51 |
| 53 | Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies. <i>European Journal of Haematology</i> , 2009, 82, 350-353. | 1.1 | 83 |
| 54 | Karyotype complements the International Prognostic Scoring System for primary myelofibrosis. <i>European Journal of Haematology</i> , 2009, 82, 255-259. | 1.1 | 58 |
| 55 | Conventional cytogenetics in myelofibrosis: literature review and discussion. <i>European Journal of Haematology</i> , 2009, 82, 329-338. | 1.1 | 107 |
| 56 | Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance. <i>European Journal of Haematology</i> , 2009, 83, 17-21. | 1.1 | 61 |
| 57 | Fast and reliable mutation detection of the complete exon 11%15 <i>JAK2</i> coding region using non-isotopic RNase cleavage assay (NIRCA). <i>European Journal of Haematology</i> , 2009, 83, 215-219. | 1.1 | 4 |
| 58 | The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan. <i>European Journal of Haematology</i> , 2009, 83, 328-333. | 1.1 | 27 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 59 | Tel/PDGFR ^{Î²} induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways. <i>Experimental Hematology</i> , 2009, 37, 111-121.e3. | 0.2 | 13 |
| 60 | Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms ^{âˆ’} . <i>Experimental Hematology</i> , 2009, 37, 1194-1200. | 0.2 | 12 |
| 61 | JAK2 V617F/C618R mutation in a patient with polycythemia vera:A case study and review of the literature. <i>Cancer Genetics and Cytogenetics</i> , 2009, 189, 43-47. | 1.0 | 23 |
| 62 | BCR ^{â€} ABL positive chronic myeloid leukemia with concurrent <i>JAK2</i>^{<i>V617F</i>} positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS ^{â€}). <i>American Journal of Hematology</i> , 2009, 84, 306-307. | 2.0 | 15 |
| 63 | Pseudo ^{â€} bowel obstruction due to varicella zoster virus infection after autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2009, 84, 127-128. | 2.0 | 11 |
| 64 | Genetic origins and clinical phenotype of familial and acquired erythrocytosis and thrombocytosis. <i>American Journal of Hematology</i> , 2009, 84, 46-54. | 2.0 | 22 |
| 65 | Optimal response to 100 ^{Î¼} g/kg anti ^{â€} Rh(D) in two patients who had suboptimal responses to 75 ^{Î¼} g/kg anti ^{â€} Rh(D). <i>American Journal of Hematology</i> , 2009, 84, 124-124. | 2.0 | 2 |
| 66 | Jakking up tumor registry reporting of the myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2009, 84, 124-126. | 2.0 | 10 |
| 67 | Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2009, 84, 126-127. | 2.0 | 28 |
| 68 | Essential thrombocythemia in patients with platelet counts below 600x10 ⁹ /L: Applicability of the 2008 World Health Organization diagnostic criteria revision proposal. <i>American Journal of Hematology</i> , 2009, 84, 452-454. | 2.0 | 2 |
| 69 | Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry. <i>American Journal of Hematology</i> , 2009, 84, 636-640. | 2.0 | 75 |
| 70 | Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations. <i>American Journal of Hematology</i> , 2009, 84, 629-630. | 2.0 | 30 |
| 71 | Prodromal myeloproliferative neoplasms: The 2008 WHO classification. <i>American Journal of Hematology</i> , 2010, 85, 62-69. | 2.0 | 84 |
| 72 | Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon ^{â€} alpha, hydroxyurea, imatinib mesylate or 2 ^{â€} chlorodeoxyadenosine. <i>American Journal of Hematology</i> , 2009, 84, 790-794. | 2.0 | 166 |
| 73 | Imbalance of DNA ^{â€} dependent protein kinase subunits in polycythemia vera peripheral blood stem cells. <i>International Journal of Cancer</i> , 2009, 124, 600-607. | 2.3 | 1 |
| 74 | The 2008 World Health Organization classification system for myeloproliferative neoplasms. <i>Cancer</i> , 2009, 115, 3842-3847. | 2.0 | 206 |
| 75 | Expression of adhesion factor CD239 in bone marrow cells in chronic myeloproliferative diseases. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 299-303. | 1.0 | 0 |
| 76 | Successful treatment of myeloid neoplasms associated with PDGFRA rearrangement with imatinib mesylate. <i>International Journal of Hematology</i> , 2009, 89, 66-70. | 0.7 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 77 | Comparison of clinicopathologic findings according to JAK2 V617F mutation in patients with essential thrombocythemia. <i>International Journal of Hematology</i> , 2009, 89, 39-44. | 0.7 | 11 |
| 78 | The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. <i>Current Hematologic Malignancy Reports</i> , 2009, 4, 33-40. | 1.2 | 75 |
| 79 | Highlights of 2008 in bone marrow biopsy pathology. <i>Journal of Hematopathology</i> , 2009, 2, 42-44. | 0.2 | 1 |
| 80 | Recent advances in bone marrow biopsy pathology. <i>Journal of Hematopathology</i> , 2009, 2, 151-156. | 0.2 | 0 |
| 81 | Isolated molecular relapse in FIP1L1-PDGFR \hat{I} ± hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 1161-1163. | 1.1 | 3 |
| 82 | Un piÃ©ge diagnostique Ã Ã©viter : Ã propos d'Ã©un cas d'hyperplaquettose de d'couverte fortuite. <i>Revue Francophone Des Laboratoires</i> , 2009, 2009, 85-88. | 0.0 | 1 |
| 83 | Non ST-segment elevation myocardial infarction in patient with essential thrombocythemia. <i>Thrombosis Journal</i> , 2009, 7, 1. | 0.9 | 9 |
| 84 | Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS) a necessary or useful diagnostic category?. <i>British Journal of Haematology</i> , 2009, 144, 809-817. | 1.2 | 34 |
| 85 | The hypereosinophilic syndromes: current concepts and treatments. <i>British Journal of Haematology</i> , 2009, 145, 271-285. | 1.2 | 113 |
| 86 | Different lineage involvement in myelodysplastic/myeloproliferative disease with combined <i>MPL</i> ^{W515L} and <i>JAK2</i> ^{V617F} mutation. <i>British Journal of Haematology</i> , 2009, 145, 673-675. | 1.2 | 17 |
| 87 | Identification of new target molecules <i>PTK2</i> , <i>TGFBR2</i> and <i>CD9</i> overexpressed during advanced bone marrow remodelling in primary myelofibrosis. <i>British Journal of Haematology</i> , 2009, 146, 510-520. | 1.2 | 18 |
| 88 | Associated cancers in parents and offspring of polycythaemia vera and myelofibrosis patients. <i>British Journal of Haematology</i> , 2009, 147, 526-530. | 1.2 | 7 |
| 89 | FIP1L1-PDGFR \hat{I} ± D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFR \hat{I} ± T674I eosinophilic leukemia with single agent sorafenib. <i>Leukemia</i> , 2009, 23, 845-851. | 3.3 | 123 |
| 90 | Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFR \hat{I} ± correlates. <i>Leukemia</i> , 2009, 23, 900-904. | 3.3 | 251 |
| 91 | CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. <i>Leukemia</i> , 2009, 23, 1441-1445. | 3.3 | 181 |
| 92 | The complete evaluation of erythrocytosis: congenital and acquired. <i>Leukemia</i> , 2009, 23, 834-844. | 3.3 | 102 |
| 93 | Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. <i>Leukemia</i> , 2009, 23, 1343-1345. | 3.3 | 255 |
| 94 | Functional characterization of an activating TEK mutation in acute myeloid leukemia: a cellular context-dependent activating mutation. <i>Leukemia</i> , 2009, 23, 1345-1348. | 3.3 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 95 | Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms. <i>Leukemia</i> , 2009, 23, 1577-1586. | 3.3 | 15 |
| 96 | Kinase drug discovery approaches in chronic myeloproliferative disorders. <i>Oncogene</i> , 2009, 28, 2305-2313. | 2.6 | 32 |
| 97 | JAK2-V617F mutation in cerebral venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1039-1040. | 1.9 | 6 |
| 98 | Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1587-1589. | 1.9 | 30 |
| 99 | Bone marrow disorders with associated eosinophilia. <i>Diagnostic Histopathology</i> , 2009, 15, 107-115. | 0.2 | 5 |
| 100 | Is JAK2 V617F mutation more than a diagnostic index?. <i>Leukemia Research</i> , 2009, 33, 67-73. | 0.4 | 108 |
| 101 | Oligonucleotide array CGH studies in myeloproliferative neoplasms: Comparison with JAK2V617F mutational status and conventional chromosome analysis. <i>Leukemia Research</i> , 2009, 33, 662-664. | 0.4 | 18 |
| 102 | Preclinical and clinical experience with dasatinib in philadelphia chromosome-negative leukemias and myeloid disorders. <i>Leukemia Research</i> , 2009, 33, 617-623. | 0.4 | 8 |
| 103 | Validation of a new three-color fluorescence in situ hybridization (FISH) method to detect CHIC2 deletion, FIP1L1/PDGFR α fusion and PDGFR α translocations. <i>Leukemia Research</i> , 2009, 33, 843-846. | 0.4 | 17 |
| 104 | Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: Efficacy of second-generation tyrosine kinase inhibitors. <i>Leukemia Research</i> , 2009, 33, 1144-1146. | 0.4 | 34 |
| 105 | Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders. <i>Blood Reviews</i> , 2009, 23, 157-165. | 2.8 | 71 |
| 106 | Decreased serum prohepcidin concentration in patients with polycythemia vera. <i>Journal of Zhejiang University: Science B</i> , 2009, 10, 791-795. | 1.3 | 9 |
| 107 | Bioluminometric Assay for Relative Quantification of Mutant Allele Burden: Application to the Oncogenic Somatic Point Mutation JAK2 V617F. <i>Analytical Chemistry</i> , 2009, 81, 8596-8602. | 3.2 | 7 |
| 108 | Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: Clinical implications. <i>Cancer Letters</i> , 2009, 284, 7-14. | 3.2 | 9 |
| 111 | Blue (or purple) toe syndrome. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 1-20. | 0.6 | 255 |
| 112 | Les syndromes myéloprolifératifs. <i>Immuno-Analyse Et Biologie Spécialisée</i> , 2009, 24, 69-85. | 0.0 | 1 |
| 113 | Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. <i>Blood</i> , 2009, 113, 6403-6410. | 0.6 | 351 |
| 114 | Analysis of the Ten-Eleven Translocation 2 (TET2) gene in familial myeloproliferative neoplasms. <i>Blood</i> , 2009, 114, 1628-1632. | 0.6 | 96 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 115 | Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis. <i>Expert Review of Hematology</i> , 2009, 2, 315-334. | 1.0 | 26 |
| 116 | Hypereosinophilic Syndrome: Current Approach to Diagnosis and Treatment. <i>Annual Review of Medicine</i> , 2009, 60, 293-306. | 5.0 | 72 |
| 117 | Myeloproliferative Neoplasms: Thrombophilic Clonal Stem Cell Diseases. <i>Cancer Treatment and Research</i> , 2009, 148, 157-179. | 0.2 | 4 |
| 119 | Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms. <i>Genome Medicine</i> , 2009, 1, 55. | 3.6 | 7 |
| 120 | JAK2V617F: more than a clonal marker?. <i>Leukemia and Lymphoma</i> , 2009, 50, 154-155. | 0.6 | 0 |
| 121 | Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 627-637. | 12.5 | 117 |
| 122 | Myeloproliferative Disorders and the Hyperviscosity Syndrome. <i>Emergency Medicine Clinics of North America</i> , 2009, 27, 459-476. | 0.5 | 30 |
| 123 | The Myeloproliferative Neoplasms: Insights into Molecular Pathogenesis and Changes in WHO Classification and Criteria for Diagnosis. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 693-708. | 0.9 | 7 |
| 125 | Alemtuzumab Therapy for Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia. <i>Clinical Cancer Research</i> , 2009, 15, 368-373. | 3.2 | 67 |
| 126 | Successful Treatment of KIT D816V-positive, Imatinib-resistant Systemic Mastocytosis with Interferon-alpha. <i>Internal Medicine</i> , 2009, 48, 1973-1978. | 0.3 | 17 |
| 127 | Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation. <i>Thrombosis and Haemostasis</i> , 2009, 101, 547-551. | 1.8 | 15 |
| 128 | CD146+ bone marrow osteoprogenitors increase in the advanced stages of primary myelofibrosis. <i>Haematologica</i> , 2009, 94, 127-130. | 1.7 | 33 |
| 129 | Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. <i>Haematologica</i> , 2009, 94, 38-45. | 1.7 | 82 |
| 130 | Biclonal expansion and heterogeneous lineage involvement in a case of chronic myeloproliferative disease with concurrent MPLW515L/JAK2V617F mutation. <i>Blood</i> , 2009, 113, 1391-1392. | 0.6 | 26 |
| 131 | Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. <i>Blood</i> , 2009, 113, 5942-5950. | 0.6 | 75 |
| 132 | Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. <i>Blood</i> , 2009, 113, 6182-6192. | 0.6 | 349 |
| 133 | Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. <i>Blood</i> , 2009, 114, 5024-5033. | 0.6 | 165 |
| 134 | Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study. <i>Haematologica</i> , 2009, 94, 865-869. | 1.7 | 45 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 136 | Churgâ€“Strauss syndrome: evidence for disease subtypes?. <i>Current Opinion in Rheumatology</i> , 2010, 22, 21-28. | 2.0 | 103 |
| 137 | Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. <i>Haematologica</i> , 2010, 95, 738-744. | 1.7 | 72 |
| 138 | Modeling the human 8p11-myeloproliferative syndrome in immunodeficient mice. <i>Blood</i> , 2010, 116, 2103-2111. | 0.6 | 20 |
| 139 | New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases. <i>Blood</i> , 2010, 116, 2429-2437. | 0.6 | 90 |
| 140 | Lyn- and PLC-Î²3â€“dependent regulation of SHP-1 phosphorylation controls Stat5 activity and myelomonocytic leukemia-like disease. <i>Blood</i> , 2010, 116, 6003-6013. | 0.6 | 58 |
| 141 | Detection of the JAK2V617F mutation with the Ipsogen MutaScreen kit: absence of JAK2V617F does not mean absence of myeloproliferative neoplasm. <i>Blood</i> , 2010, 116, 1994-1995. | 0.6 | 1 |
| 142 | Rare thromboses of cerebral, splanchnic and upper-extremity veins. <i>Thrombosis and Haemostasis</i> , 2010, 103, 1136-1144. | 1.8 | 48 |
| 143 | Myeloproliferative Neoplasms: New Translational Therapies. <i>Mount Sinai Journal of Medicine</i> , 2010, 77, 667-683. | 1.9 | 7 |
| 144 | Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. <i>Annals of Hematology</i> , 2010, 89, 141-146. | 0.8 | 39 |
| 145 | Essential thrombocythemia as underlying cause of malabsorption syndrome. <i>Annals of Hematology</i> , 2010, 89, 1067-1068. | 0.8 | 0 |
| 146 | The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms. <i>Annals of Hematology</i> , 2010, 89, 979-983. | 0.8 | 25 |
| 148 | Visual screening for JAK2V617F mutation by a disposable dipstick. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 397, 1911-1916. | 1.9 | 11 |
| 149 | The Development of Gastric Cancer in a Patient with Polycythemia Vera, 3P Deletion, and JAK2 V617F Mutation. <i>Journal of Gastrointestinal Cancer</i> , 2010, 41, 254-256. | 0.6 | 1 |
| 150 | Circulating endothelial cells in essential thrombocythemia and polycythemia vera: correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers. <i>International Journal of Hematology</i> , 2010, 91, 792-798. | 0.7 | 27 |
| 151 | Chronic myelomonocytic leukemia with t (3; 9) (p21; p13) as a sole abnormal appearance: One case report. <i>Clinical Oncology and Cancer Research</i> , 2010, 7, 326-329. | 0.1 | 1 |
| 153 | Polycythemia vera. <i>Internal and Emergency Medicine</i> , 2010, 5, 375-384. | 1.0 | 25 |
| 154 | Proteomic analysis reveals a novel mechanism induced by the leukemic oncogene Tel/PDGFRÎ² in stem cells: Activation of the interferon response pathways. <i>Stem Cell Research</i> , 2010, 5, 226-243. | 0.3 | 9 |
| 155 | Targeted therapy of chronic myeloid leukemia. <i>Biochemical Pharmacology</i> , 2010, 80, 584-591. | 2.0 | 28 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 156 | A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes. <i>Cancer Genetics and Cytogenetics</i> , 2010, 199, 1-8. | 1.0 | 10 |
| 157 | Postimatinib therapy emergence of a new JAK2 V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia. <i>European Journal of Haematology</i> , 2010, 85, 86-87. | 1.1 | 14 |
| 158 | Treatment options for hydroxyurea refractory disease complications in myeloproliferative neoplasms: JAK2 inhibitors, radiotherapy, splenectomy and transjugular intrahepatic portosystemic shunt. <i>European Journal of Haematology</i> , 2010, 85, 192-199. | 1.1 | 24 |
| 159 | Chromosomal abnormalities in transformed Ph negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 919-927. | 1.5 | 15 |
| 160 | Liver function tests and absolute lymphocyte count at day +100 are predictive factors for extensive and severe chronic graft versus host disease after allogeneic peripheral blood stem cell transplant. <i>American Journal of Hematology</i> , 2010, 85, 290-293. | 2.0 | 2 |
| 161 | Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion independent thalassemia intermedia compared to regularly transfused thalassemia major patients. <i>American Journal of Hematology</i> , 2010, 85, 288-290. | 2.0 | 61 |
| 162 | Is the JAK2 ^{V617F} mutation detectable in healthy volunteers?. <i>American Journal of Hematology</i> , 2010, 85, 287-288. | 2.0 | 34 |
| 163 | Detection of hereditary hemochromatosis and biochemical iron overload in primary care: A multicenter case finding study in Spain. <i>American Journal of Hematology</i> , 2010, 85, 294-296. | 2.0 | 6 |
| 164 | Development of Löffler's endocarditis in FIP1L1 PDGFRalpha positive hypereosinophilic syndrome despite continuous imatinib mesylate therapy and continuous complete remission. <i>American Journal of Hematology</i> , 2010, 85, 296-299. | 2.0 | 0 |
| 165 | Cardiac tamponade or hemopericardium are not associated with bleeding risk factors in consecutive patients hospitalized with noniatrogenic, pericardial effusions. <i>American Journal of Hematology</i> , 2010, 85, 300-301. | 2.0 | 2 |
| 166 | ASH 2009 meeting report Top 10 clinically oriented abstracts in acute leukemia. <i>American Journal of Hematology</i> , 2010, 85, 277-280. | 2.0 | 1 |
| 167 | ASH 2009 meeting report Top 10 clinically oriented abstracts in lymphoma. <i>American Journal of Hematology</i> , 2010, 85, 280-283. | 2.0 | 0 |
| 168 | ASH 2009 meeting report Top 10 clinically oriented abstracts in chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2010, 85, 283-286. | 2.0 | 1 |
| 169 | Refractory anaemia with ring sideroblasts associated with marked thrombocytosis (RARS-T) and JAK2V617F mutation transformed to acute myeloid leukaemia with chromosomal evolution including monosomy 7. <i>Leukemia Research</i> , 2010, 34, e69-e70. | 0.4 | 2 |
| 170 | Aberrant proplatelet formation in chronic myeloproliferative neoplasms. <i>Leukemia Research</i> , 2010, 34, 1424-1429. | 0.4 | 17 |
| 171 | Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 2609-2613. | 1.0 | 40 |
| 172 | Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate. <i>Pediatric Blood and Cancer</i> , 2010, 55, 730-732. | 0.8 | 14 |
| 173 | New TET2 gene mutations in patients with myeloproliferative neoplasms and splanchnic vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1142-1144. | 1.9 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 174 | A case of myeloid neoplasm associated with eosinophilia and KIAA1509-PDGFR ^β responsive to combination treatment with imatinib mesylate and prednisolone. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2010, 35, 733-736. | 0.7 | 3 |
| 175 | Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias. <i>Leukemia</i> , 2010, 24, 201-203. | 3.3 | 43 |
| 176 | Characterizing chromosomal break points of t(12;21)[ETV6-RUNX1]-positive leukaemia using multiple tiling PCR on whole-genome-amplified DNA. <i>Leukemia</i> , 2010, 24, 203-205. | 3.3 | 2 |
| 177 | MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms. <i>Leukemia</i> , 2010, 24, 859-860. | 3.3 | 25 |
| 178 | IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. <i>Leukemia</i> , 2010, 24, 1302-1309. | 3.3 | 300 |
| 179 | KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia. <i>Leukemia</i> , 2010, 24, 1052-1055. | 3.3 | 39 |
| 180 | A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. <i>Leukemia</i> , 2010, 24, 1574-1579. | 3.3 | 321 |
| 181 | Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. <i>Leukemia</i> , 2010, 24, 1128-1138. | 3.3 | 499 |
| 182 | Blood Disorders in the Elderly. , 2010, , 775-790. | | 0 |
| 183 | Leucemia mieloide crônica e outras doenças mieloproliferativas crônicas. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2010, 32, 71-90. | 0.7 | 2 |
| 185 | Aberrant Myeloid Maturation Identified by Flow Cytometry in Primary Myelofibrosis. <i>American Journal of Clinical Pathology</i> , 2010, 133, 314-320. | 0.4 | 15 |
| 186 | JAK2 ^{V617F} Mutation Associated with Cerebral Venous Thrombosis: A Report of Five Cases. <i>Cerebrovascular Diseases</i> , 2010, 29, 206-209. | 0.8 | 12 |
| 187 | FIP1L1/PDGFR ^β -Associated Systemic Mastocytosis. <i>International Archives of Allergy and Immunology</i> , 2010, 152, 101-105. | 0.9 | 16 |
| 188 | Activation of JAK2-V617F by Components of Heterodimeric Cytokine Receptors. <i>Journal of Biological Chemistry</i> , 2010, 285, 16651-16663. | 1.6 | 28 |
| 189 | JAK/STAT Pathways in Cytokine Signaling and Myeloproliferative Disorders: Approaches for Targeted Therapies. <i>Genes and Cancer</i> , 2010, 1, 979-993. | 0.6 | 179 |
| 190 | A Bead-Based Activity Screen for Small-Molecule Inhibitors of Signal Transduction in Chronic Myelogenous Leukemia Cells. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1469-1481. | 1.9 | 14 |
| 191 | Hypotension, Syncope, and Fever in Systemic Mastocytosis without Skin Infiltration and Rapid Response to Corticosteroid and Cyclosporin: A Case Report. <i>Case Reports in Medicine</i> , 2010, 2010, 1-4. | 0.3 | 7 |
| 192 | Acute Myeloid Leukemia With Myeloid Sarcoma and Eosinophilia: Prolonged Remission and Molecular Response to Imatinib. <i>Journal of Clinical Oncology</i> , 2010, 28, e33-e35. | 0.8 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 193 | Autoimmunity and the risk of myeloproliferative neoplasms. <i>Haematologica</i> , 2010, 95, 1216-1220. | 1.7 | 151 |
| 194 | Myeloproliferative Disorders and the Hyperviscosity Syndrome. <i>Hematology/Oncology Clinics of North America</i> , 2010, 24, 585-602. | 0.9 | 22 |
| 195 | Hypereosinophilic Syndrome and Clonal Eosinophilia: Point-of-Care Diagnostic Algorithm and Treatment Update. <i>Mayo Clinic Proceedings</i> , 2010, 85, 158-164. | 1.4 | 146 |
| 196 | Heritability of Hematologic Malignancies: From Pedigrees to Genomics. <i>Hematology/Oncology Clinics of North America</i> , 2010, 24, 939-972. | 0.9 | 9 |
| 197 | Mutational analysis in <i>BCR-ABL</i> -negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices. <i>Leukemia and Lymphoma</i> , 2010, 51, 576-582. | 0.6 | 11 |
| 199 | <i>JAK2</i> V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. <i>Expert Review of Hematology</i> , 2010, 3, 323-337. | 1.0 | 73 |
| 200 | Amyotrophic lateral sclerosis (Lou Gehrig's disease) is caused by electric currents applied to or induced in the body: It is an iatrogenic disease of athletes caused by use of electrotherapy devices. <i>Medical Hypotheses</i> , 2010, 74, 1086-1087. | 0.8 | 2 |
| 201 | A proposal to rename and classify aplastic anemia as Myeloaplastic syndrome (MAS) Type I and II. <i>Medical Hypotheses</i> , 2010, 74, 1085-1086. | 0.8 | 0 |
| 202 | The evolving clinical scenario of myelodysplastic syndrome: The need for a complete and up to date upfront diagnostic assessment. <i>European Journal of Internal Medicine</i> , 2010, 21, 490-495. | 1.0 | 7 |
| 205 | <i>JAK2</i> gene mutation: impact on pathogenesis, classification, and management of myeloproliferative neoplasms. <i>Community Oncology</i> , 2010, 7, 109-114. | 0.2 | 2 |
| 206 | Thrombotic complications in children with haematologic malignancies. <i>Thrombosis Research</i> , 2010, 125, S151-S154. | 0.8 | 4 |
| 207 | Case 23-2010. <i>New England Journal of Medicine</i> , 2010, 363, 463-475. | 13.9 | 37 |
| 208 | Chronic Myeloid Neoplasias and Clonal Overlap Syndromes. , 2010, , . | | 1 |
| 209 | Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy and <i>JAK2</i> V617F mutational status. <i>Leukemia and Lymphoma</i> , 2010, 51, 1-7. | 0.6 | 16 |
| 210 | Molecular Pathology of Myeloproliferative Neoplasms. <i>American Journal of Clinical Pathology</i> , 2010, 133, 602-615. | 0.4 | 28 |
| 211 | Melting Point Assay for the <i>JAK2</i> V617F Mutation, Comparison with Amplification Refractory Mutation System (ARMS) in Diagnostic Samples, and Implications for Daily Routine. <i>Molecular Diagnosis and Therapy</i> , 2010, 14, 185-190. | 1.6 | 5 |
| 212 | How I treat myelofibrosis. <i>Blood</i> , 2011, 117, 3494-3504. | 0.6 | 115 |
| 213 | Non-infectious pulmonary complications of myelodysplastic syndromes and chronic myeloproliferative disorders. <i>Revue Des Maladies Respiratoires</i> , 2011, 28, e18-e27. | 1.7 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 214 | Essential Thrombocythemia and Multiple Myeloma: Two Rare Diseases in One Patient. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 442-445. | 0.2 | 12 |
| 215 | Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis. <i>Mayo Clinic Proceedings</i> , 2011, 86, 1188-1191. | 1.4 | 203 |
| 217 | Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. <i>Blood Cancer Journal</i> , 2011, 1, e7-e7. | 2.8 | 13 |
| 218 | New JAK2 inhibitors for myeloproliferative neoplasms. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 961-972. | 1.9 | 20 |
| 219 | Absolute Quantification of the Alleles in Somatic Point Mutations by Bioluminometric Methods based on Competitive Polymerase Chain Reaction in the Presence of a Locked Nucleic Acid Blocker or an Allele-Specific Primer. <i>Analytical Chemistry</i> , 2011, 83, 6545-6551. | 3.2 | 7 |
| 220 | JAK inhibitors in myeloproliferative neoplasms: Rationale, current data and perspective. <i>Blood Reviews</i> , 2011, 25, 229-237. | 2.8 | 43 |
| 221 | Pomalidomide therapy for multiple myeloma and myelofibrosis: an update. <i>Leukemia and Lymphoma</i> , 2011, 52, 560-566. | 0.6 | 10 |
| 223 | Thrombophilic dimension of Budd chiari syndrome and portal venous thrombosis – A concise review. <i>Thrombosis Research</i> , 2011, 127, 505-512. | 0.8 | 36 |
| 224 | Sex modulation of the occurrence of jak2 v617f mutation in patients with splanchnic venous thrombosis. <i>Thrombosis Research</i> , 2011, 128, 233-236. | 0.8 | 18 |
| 225 | Atypical myeloproliferative disorders in adults. <i>Transfusion and Apheresis Science</i> , 2011, 44, 211-221. | 0.5 | 7 |
| 226 | BCR-ABL1 ⁻ Negative Myeloproliferative Neoplasms: A Review of Molecular Biology, Diagnosis, and Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S37-S45. | 0.2 | 24 |
| 227 | The myeloproliferative neoplasms including the eosinophilia-related myeloproliferations associated with tyrosine kinase mutations: changes and issues in classification and diagnosis criteria. <i>Seminars in Diagnostic Pathology</i> , 2011, 28, 304-313. | 1.0 | 4 |
| 228 | Deregulated expression of A1, Bcl-2, Bcl-xL, and Mcl-1 antiapoptotic proteins and Bid, Bad, and Bax proapoptotic genes in polycythemia vera patients. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 2011, 47, 873-886. | 1.2 | 15 |
| 229 | Diagnostic and therapeutic guideline for myeloproliferative neoplasm. <i>Journal of the Korean Medical Association</i> , 2011, 54, 112. | 0.1 | 5 |
| 230 | Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. <i>Blood</i> , 2011, 117, 5710-5718. | 0.6 | 163 |
| 231 | R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm. <i>Blood</i> , 2011, 117, 6866-6875. | 0.6 | 23 |
| 232 | The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. <i>Haematologica</i> , 2011, 96, 367-374. | 1.7 | 67 |
| 233 | Successful Treatment of Ulcerative Colitis Associated with Hypereosinophilic Syndrome/Chronic Eosinophilic Leukemia. <i>Internal Medicine</i> , 2011, 50, 1741-1745. | 0.3 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 234 | Pathogenesis of early leukemia and lymphoma. <i>Cancer Biomarkers</i> , 2011, 9, 341-374. | 0.8 | 6 |
| 235 | JAK2 V617F mutation negative erythrocytosis (or how to more simply perform diagnosis and treat a Tj ETQq1 1 0.784314 rgBT /Over | 0.6 | 0 |
| 236 | Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2208-2214. | 1.9 | 68 |
| 237 | Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 127-140. | 21.5 | 261 |
| 238 | The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro. <i>Oncogene</i> , 2011, 30, 933-943. | 2.6 | 28 |
| 239 | JAK2V617F mutation in patients with thrombosis: to screen or not to screen?. <i>International Journal of Laboratory Hematology</i> , 2011, 33, 117-124. | 0.7 | 35 |
| 240 | Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis. <i>International Journal of Laboratory Hematology</i> , 2011, 33, 471-476. | 0.7 | 9 |
| 241 | The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera. <i>European Journal of Haematology</i> , 2011, 86, 148-155. | 1.1 | 59 |
| 242 | Alternately binding probe competitive PCR as a simple, cost-effective, and accurate quantification method for JAK2V617F allele burden in myeloproliferative neoplasms. <i>Leukemia Research</i> , 2011, 35, 1632-1636. | 0.4 | 17 |
| 243 | Identification of JAK2 mutations in canine primary polycythemia. <i>Experimental Hematology</i> , 2011, 39, 542-545. | 0.2 | 23 |
| 244 | Thrombospondin-1 (TSP-1) in primary myelofibrosis (PMF) – a megakaryocyte-derived biomarker which largely discriminates PMF from essential thrombocythemia. <i>Annals of Hematology</i> , 2011, 90, 33-40. | 0.8 | 22 |
| 245 | The role of zinc protoporphyrin measurement in the differentiation between primary myelofibrosis and essential thrombocythaemia. <i>Annals of Hematology</i> , 2011, 90, 389-394. | 0.8 | 2 |
| 246 | Asymmetric dimethylarginine levels in essential thrombocythemia – a retrospective analysis. <i>Annals of Hematology</i> , 2011, 90, 1105-1106. | 0.8 | 0 |
| 247 | Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study. <i>Annals of Hematology</i> , 2011, 90, 933-938. | 0.8 | 61 |
| 248 | Philadelphia-negative myeloproliferative Neoplasien. <i>Wiener Klinische Wochenschrift Education</i> , 2011, 6, 35-48. | 0.0 | 0 |
| 249 | Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series: Polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2011, 86, 292-301. | 2.0 | 35 |
| 251 | JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis. <i>American Journal of Hematology</i> , 2011, 86, 526-528. | 2.0 | 31 |
| 252 | Vinblastine in the treatment of children and adolescents with refractory immune thrombocytopenia. <i>American Journal of Hematology</i> , 2011, 86, 785-787. | 2.0 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 253 | Prognostic significance of delayed thrombocytopenia after allogeneic stem cell transplant. American Journal of Hematology, 2011, 86, 790-792. | 2.0 | 20 |
| 254 | Sideroblastic anemia, iron overload, and ALAS2R452S in African-American males: Phenotype and genotype features of five unrelated patients. American Journal of Hematology, 2011, 86, 787-789. | 2.0 | 3 |
| 255 | Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: A phase I study. American Journal of Hematology, 2011, 86, 796-800. | 2.0 | 39 |
| 256 | An evaluation of concurrent G6PD (A ⁺) deficiency and sickle cell trait in Malian populations of children with severe or uncomplicated P. falciparum malaria. American Journal of Hematology, 2011, 86, 795-796. | 2.0 | 9 |
| 257 | Published guidelines versus real-life practice in the diagnosis and treatment of essential thrombocythemia. American Journal of Hematology, 2011, 86, 792-794. | 2.0 | 3 |
| 258 | Clinical and laboratory features of leukemias at the time of diagnosis: An analysis of 1,004 consecutive patients. American Journal of Hematology, 2011, 86, 800-803. | 2.0 | 0 |
| 259 | Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease. American Journal of Hematology, 2011, 86, 804-806. | 2.0 | 25 |
| 260 | Changing patterns of splenectomy in transfusion-dependent thalassemia patients. American Journal of Hematology, 2011, 86, 808-810. | 2.0 | 32 |
| 261 | Increased prevalence of osteonecrosis of the femoral head in children and adolescents with sickle cell disease. American Journal of Hematology, 2011, 86, 806-808. | 2.0 | 46 |
| 262 | When children with sickle cell disease become adults: Lack of outpatient care leads to increased use of the emergency department. American Journal of Hematology, 2011, 86, 863-865. | 2.0 | 67 |
| 263 | Possible new LNK mutations in myeloproliferative neoplasms. American Journal of Hematology, 2011, 86, 866-868. | 2.0 | 18 |
| 264 | Concomitant lupus anticoagulant and monoclonal IgM ⁺ antibody in a patient with bleeding tendency: A case report and literature review. American Journal of Hematology, 2011, 86, 868-871. | 2.0 | 1 |
| 265 | Cyclophosphamide and prednisone induction followed by cyclophosphamide mobilization effectively decreases the incidence of engraftment syndrome in patients with POEMS syndrome who undergo stem cell transplantation. American Journal of Hematology, 2011, 86, 873-875. | 2.0 | 20 |
| 266 | Treatment of vitamin D deficiency in transfusion-dependent thalassemia. American Journal of Hematology, 2011, 86, 871-873. | 2.0 | 36 |
| 267 | Circulating cytokine levels, Epstein-Barr viremia, and risk of acquired immunodeficiency syndrome-related non-Hodgkin lymphoma. American Journal of Hematology, 2011, 86, 875-878. | 2.0 | 17 |
| 268 | Basophils and plasmacytoid dendritic cells are potential sources for error in flow cytometric monitoring of patients receiving anti-CD22 therapies. AKA not all anti-CD22 antibodies are created equal. American Journal of Hematology, 2011, 86, 891-892. | 2.0 | 6 |
| 269 | Managing cardiac amyloidosis: Auto or allotransplant?. American Journal of Hematology, 2011, 86, 885-886. | 2.0 | 0 |
| 270 | Hydroxyurea use in patients with sickle cell disease in a Medicaid population. American Journal of Hematology, 2011, 86, 888-890. | 2.0 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 271 | Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias. <i>American Journal of Hematology</i> , 2011, 86, 882-884. | 2.0 | 16 |
| 272 | Peritransplant palifermin use and lymphocyte recovery after Tâ€cell replete, matched related allogeneic hematopoietic cell transplantation. <i>American Journal of Hematology</i> , 2011, 86, 879-882. | 2.0 | 17 |
| 273 | Successful treatment with recombinant soluble thrombomodulin of two cases of sinusoidal obstructive syndrome/hepatic veno-occlusive disease after bone marrow transplantation. <i>American Journal of Hematology</i> , 2011, 86, 886-888. | 2.0 | 17 |
| 274 | Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia. <i>American Journal of Hematology</i> , 2011, 86, 860-862. | 2.0 | 87 |
| 275 | Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2011, 86, 1017-1026. | 2.0 | 45 |
| 276 | Experimental therapeutics for patients with myeloproliferative neoplasias. <i>Cancer</i> , 2011, 117, 662-676. | 2.0 | 18 |
| 277 | In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 2958-2961. | 1.0 | 14 |
| 278 | Polycythemia vera evolving into a rapidly progressive Ph-negative del(5q)-positive myeloproliferative neoplasm refractory to lenalidomide. <i>Leukemia Research</i> , 2011, 35, e41-e43. | 0.4 | 1 |
| 279 | Current Treatment Concepts of Philadelphia-Negative MPN. <i>Current Cancer Drug Targets</i> , 2011, 11, 44-55. | 0.8 | 8 |
| 280 | Reproducibility of Histologic Classification in Nonfibrotic Myeloproliferative Neoplasia. <i>American Journal of Clinical Pathology</i> , 2011, 136, 618-624. | 0.4 | 26 |
| 281 | Bilateral renal vein thrombosis due to inapparent polycythaemia. <i>CKJ: Clinical Kidney Journal</i> , 2011, 4, 244-245. | 1.4 | 1 |
| 282 | Development of Polycythemia Vera after Chemotherapy-Induced Remission of Acute Myeloid Leukemia: A Case Report. <i>Acta Haematologica</i> , 2011, 126, 52-53. | 0.7 | 9 |
| 283 | Aggressive Systemic Mastocytosis Associated with Mesangioproliferative Glomerulonephritis. <i>Acta Haematologica</i> , 2011, 125, 153-159. | 0.7 | 7 |
| 284 | An 8-Year-Old Boy with Hypereosinophilic Syndrome. <i>International Archives of Allergy and Immunology</i> , 2011, 155, 117-122. | 0.9 | 11 |
| 285 | Differential expression of apoptosis-related genes from death receptor pathway in chronic myeloproliferative diseases. <i>Journal of Clinical Pathology</i> , 2011, 64, 75-82. | 1.0 | 32 |
| 286 | Essential thrombocythemia and primary myelofibrosis. , 2011, , 347-359. | | 0 |
| 287 | Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 3179-3184. | 0.8 | 441 |
| 288 | Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2011, 29, 789-796. | 0.8 | 369 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 290 | Rituximab for managing acquired hemophilia A in a case of chronic neutrophilic leukemia with the JAK2 kinase V617F mutation. <i>Journal of Blood Medicine</i> , 2012, 3, 157. | 0.7 | 15 |
| 291 | Spontaneous Regression of Follicular Dendritic Cell Sarcoma. <i>Journal of Clinical Oncology</i> , 2012, 30, e24-e26. | 0.8 | 12 |
| 292 | Pathology Consultation on Myeloproliferative Neoplasms. <i>American Journal of Clinical Pathology</i> , 2012, 138, 12-19. | 0.4 | 3 |
| 293 | JAK2V617F allele burden is associated with transformation to myelofibrosis. <i>Leukemia and Lymphoma</i> , 2012, 53, 2210-2213. | 0.6 | 22 |
| 294 | Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. <i>Blood</i> , 2012, 120, 1202-1209. | 0.6 | 205 |
| 295 | Clonal evolution in UKE-1 cell line leading to an increase in JAK2 copy number. <i>Blood Cancer Journal</i> , 2012, 2, e66-e66. | 2.8 | 9 |
| 296 | Does increasing the JAK2V617F assay sensitivity allow to identify more patients with MPN?. <i>Blood Cancer Journal</i> , 2012, 2, e70-e70. | 2.8 | 4 |
| 297 | Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms. <i>FASEB Journal</i> , 2012, 26, 894-906. | 0.2 | 40 |
| 298 | A novel, highly sensitive and rapid allele-specific loop-mediated amplification assay for the detection of the JAK2V617F mutation in chronic myeloproliferative neoplasms. <i>Haematologica</i> , 2012, 97, 1394-1400. | 1.7 | 21 |
| 299 | Complete Response of Myeloid Sarcoma with FIP1L1-PDGFR α -Associated Myeloproliferative Neoplasms to Imatinib Mesylate Monotherapy. <i>Acta Haematologica</i> , 2012, 128, 83-87. | 0.7 | 6 |
| 300 | Current and Emerging Therapies in Primary Myelofibrosis. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2012, 12, 6-20. | 0.2 | 1 |
| 301 | Current treatment practices for essential thrombocythemia: survey results from European hematologists/oncologists. <i>Hematology</i> , 2012, 17, 187-192. | 0.7 | 2 |
| 302 | Imatinib and Beyond – Targeting Activated Tyrosine Kinases in Myeloproliferative Disorders. <i>Onkologie</i> , 2012, 35, 34-41. | 1.1 | 3 |
| 303 | Testosterone replacement therapy and polycythemia in HIV-infected patients. <i>Aids</i> , 2012, 26, 243-245. | 1.0 | 9 |
| 304 | A 32-Year-Old Man With Persistent Cough, Shortness of Breath, Eosinophilic Pneumonia, and Peripheral Blood Eosinophilia. <i>Chest</i> , 2012, 142, 1680-1683. | 0.4 | 6 |
| 305 | Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib. <i>Current Medicinal Chemistry</i> , 2012, 19, 4399-4413. | 1.2 | 82 |
| 307 | CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2. <i>Haematologica</i> , 2012, 97, 1234-1241. | 1.7 | 19 |
| 308 | A risk of essential thrombocythemia in carriers of constitutional CHEK2 gene mutations. <i>Haematologica</i> , 2012, 97, 366-370. | 1.7 | 18 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 309 | Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera. <i>Haematologica</i> , 2012, 97, 538-542. | 1.7 | 31 |
| 311 | The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. <i>Blood</i> , 2012, 119, 2657-2664. | 0.6 | 133 |
| 312 | Unique features of primary myelofibrosis in Chinese. <i>Blood</i> , 2012, 119, 2469-2473. | 0.6 | 37 |
| 313 | A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera. <i>Blood</i> , 2012, 119, 5221-5228. | 0.6 | 37 |
| 314 | A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. <i>New England Journal of Medicine</i> , 2012, 366, 799-807. | 13.9 | 1,738 |
| 316 | Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 607-612.e9. | 1.5 | 604 |
| 318 | The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 388-396. | 1.0 | 23 |
| 319 | One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience. <i>Mayo Clinic Proceedings</i> , 2012, 87, 25-33. | 1.4 | 181 |
| 320 | ICON: Eosinophil Disorders. <i>World Allergy Organization Journal</i> , 2012, 5, 174-181. | 1.6 | 25 |
| 321 | Absence of BRAF V600E mutation in a cohort of 402 patients with various chronic and acute myeloid neoplasms. <i>Leukemia and Lymphoma</i> , 2012, 53, 2496-2497. | 0.6 | 13 |
| 322 | How I treat polycythemia vera. <i>Blood</i> , 2012, 120, 275-284. | 0.6 | 74 |
| 323 | Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. <i>Blood</i> , 2012, 119, 2219-2227. | 0.6 | 78 |
| 324 | Absence of JAK2V617F mutation in Chinese deep vein thrombosis patients without myeloproliferative neoplasms. <i>Thrombosis Research</i> , 2012, 129, 664-665. | 0.8 | 0 |
| 325 | The Role of Janus Kinases in Hematopoietic Malignancies. , 2012, , 239-258. | | 1 |
| 326 | Janus Kinase Deregulation in Leukemia and Lymphoma. <i>Immunity</i> , 2012, 36, 529-541. | 6.6 | 107 |
| 327 | Why Does My Patient Have Thrombocytosis?. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 285-301. | 0.9 | 27 |
| 328 | COLD-PCR and Innovative Microarray Substrates for Detecting and Genotyping MPL Exon 10 W515 Substitutions. <i>Clinical Chemistry</i> , 2012, 58, 1692-1702. | 1.5 | 9 |
| 329 | How to manage polycythemia vera. <i>Leukemia</i> , 2012, 26, 870-874. | 3.3 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 330 | Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. <i>Blood</i> , 2012, 120, 569-571. | 0.6 | 69 |
| 331 | Role of Germline Genetic Factors in MPN Pathogenesis. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 1037-1051. | 0.9 | 17 |
| 333 | Therapeutic Approaches to Patients With Hypereosinophilic Syndromes. <i>Seminars in Hematology</i> , 2012, 49, 160-170. | 1.8 | 27 |
| 334 | Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications. <i>Blood Cells, Molecules, and Diseases</i> , 2012, 49, 170-176. | 0.6 | 43 |
| 335 | Abdominal thromboses of splanchnic, renal and ovarian veins. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 253-264. | 0.7 | 27 |
| 336 | Case of polycythemia vera concurrent with FIP1L1-PDGFR α positive myeloproliferative neoplasm with eosinophilia. <i>Cancer Genetics</i> , 2012, 205, 519-522. | 0.2 | 2 |
| 337 | Incidence Rates and Risk Factors for Vascular Events in Patients With Essential Thrombocythemia: A Multicenter Study From Korea. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 70-75. | 0.2 | 16 |
| 338 | Síndromes mieloproliferativos. <i>Medicine</i> , 2012, 11, 1289-1297. | 0.0 | 1 |
| 339 | Síndromes hipereosinofílicos. Mastocitosis sistémicas. <i>Medicine</i> , 2012, 11, 1298-1308. | 0.0 | 0 |
| 340 | Janus kinase (JAK) 2 V617F mutation in Asian Indians with cerebral venous thrombosis and without overt myeloproliferative disorders. <i>Journal of the Neurological Sciences</i> , 2012, 323, 178-182. | 0.3 | 18 |
| 341 | Myeloproliferative neoplasms 2012: The John M. Bennett 80th birthday anniversary lecture. <i>Leukemia Research</i> , 2012, 36, 1481-1489. | 0.4 | 17 |
| 342 | An update on the diagnosis and management of Budd-Chiari syndrome. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 731-744. | 1.4 | 35 |
| 344 | Impaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: correlation with JAK2V617F mutational status and cytoreductive therapy. <i>Medical Oncology</i> , 2012, 29, 2388-2395. | 1.2 | 13 |
| 345 | New pieces of a puzzle: The current biological picture of MPN. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2012, 1826, 415-422. | 3.3 | 6 |
| 346 | Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. <i>Expert Review of Hematology</i> , 2012, 5, 157-176. | 1.0 | 140 |
| 347 | Correlations between Janus Kinase 2 V617F Allele Burdens and Clinicohematologic Parameters in Myeloproliferative Neoplasms. <i>Annals of Laboratory Medicine</i> , 2012, 32, 385-391. | 1.2 | 31 |
| 348 | Pregnancy and spontaneous delivery in a patient with primary myelofibrosis. <i>Journal of Neonatal-Perinatal Medicine</i> , 2012, 5, 393-395. | 0.4 | 0 |
| 349 | Approach to the diagnosis and classification of blood diseases. , 2012, , 549-562. | | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 350 | Influence of interferon- γ treatment outcome in polycythemia vera and essential thrombocythemia by genetic polymorphism in IL28B. <i>Journal of Hematological Malignancies</i> , 2012, 2, . | 0.0 | 0 |
| 351 | Anaphylactic shock in a patient with mastocytosis. <i>Medical Journal of Australia</i> , 2012, 197, 520-521. | 0.8 | 2 |
| 352 | Does Thrombocyte Size Give Us an Idea about Thrombocytosis Etiology?. <i>Scientific World Journal</i> , The, 2012, 2012, 1-5. | 0.8 | 7 |
| 353 | The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population. <i>BMC Medical Genetics</i> , 2012, 13, 6. | 2.1 | 14 |
| 354 | A portable and integrated nucleic acid amplification microfluidic chip for identifying bacteria. <i>Lab on A Chip</i> , 2012, 12, 1495. | 3.1 | 76 |
| 355 | Polycythemia as rare secondary direct manifestation of acromegaly: management and single-centre epidemiological data. <i>Pituitary</i> , 2012, 15, 209-214. | 1.6 | 7 |
| 356 | Transient floating thrombus of the internal carotid artery associated with the JAK2V617F mutation. <i>Journal of Neurology</i> , 2012, 259, 1234-1235. | 1.8 | 1 |
| 357 | Clinical course and molecular features in 21 patients with atypical chronic myeloid leukemia. <i>International Journal of Laboratory Hematology</i> , 2012, 34, e3-5. | 0.7 | 20 |
| 358 | The JAK2V617F mutation in patients with cerebral venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 998-1003. | 1.9 | 61 |
| 359 | Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis. <i>Journal of Hematology and Oncology</i> , 2012, 5, 2. | 6.9 | 40 |
| 360 | Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2012, 87, 175-182. | 2.0 | 35 |
| 361 | Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2012, 87, 284-293. | 2.0 | 153 |
| 362 | A novel mutation in MPL (Y252H) results in increased thrombopoietin sensitivity in essential thrombocythemia. <i>American Journal of Hematology</i> , 2012, 87, 532-534. | 2.0 | 17 |
| 363 | Thrombocytosis in rheumatoid arthritis: JAK2V617F-positive essential thrombocythemia. <i>Rheumatology International</i> , 2012, 32, 269-271. | 1.5 | 10 |
| 364 | Relevance of the JAK2V617F mutation in patients with deep vein thrombosis of the leg. <i>Annals of Hematology</i> , 2012, 91, 103-107. | 0.8 | 8 |
| 365 | Different mutations of the human c-mpl gene indicate distinct haematopoietic diseases. <i>Journal of Hematology and Oncology</i> , 2013, 6, 11. | 6.9 | 28 |
| 366 | A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. <i>British Journal of Haematology</i> , 2013, 162, 498-508. | 1.2 | 65 |
| 367 | Acute Myeloid Leukemia Following a Myeloproliferative Neoplasm: Clinical Characteristics, Genetic Features and Effects of Therapy. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 116-122. | 1.2 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 368 | Simple and Complex. <i>New England Journal of Medicine</i> , 2013, 368, 65-71. | 13.9 | 5 |
| 369 | A phase II study of <sc>G</sc>ivinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. <i>British Journal of Haematology</i> , 2013, 161, 688-694. | 1.2 | 109 |
| 370 | Personalized management of essential thrombocythemia—application of recent evidence to clinical practice. <i>Leukemia</i> , 2013, 27, 1617-1620. | 3.3 | 49 |
| 372 | Myeloproliferative neoplasms in five multiple sclerosis patients. <i>Leukemia Research Reports</i> , 2013, 2, 61-63. | 0.2 | 4 |
| 373 | Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: A role for the JAK2 V617F mutation re-evaluation. <i>Thrombosis Research</i> , 2013, 132, e99-e104. | 0.8 | 34 |
| 374 | Liver in haematological disorders. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2013, 27, 513-530. | 1.0 | 19 |
| 375 | Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1285-1292. | 0.8 | 171 |
| 376 | WHO Classification of Myeloproliferative Neoplasms (MPN): A Critical Update. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 333-341. | 1.2 | 19 |
| 377 | A Multiplexed Fragment Analysis-Based Assay for Detection of JAK2 Exon 12 Mutations. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 592-599. | 1.2 | 20 |
| 378 | Splanchnic vein thrombosis in myeloproliferative neoplasms. <i>British Journal of Haematology</i> , 2013, 162, 730-747. | 1.2 | 56 |
| 380 | No association between the <i><sc>STAT</sc>5b</i> rs6503691 (C>T) <sc>SNP</sc> and myeloproliferative neoplasms. <i>European Journal of Haematology</i> , 2013, 90, 257-258. | 1.1 | 3 |
| 381 | Endogenous Erythroid Colony Formation in Chronic Myeloid Leukemia: A Recurrent Finding Associated with Persistent Minimal Residual Disease Under Imatinib. <i>Stem Cells and Development</i> , 2013, 22, 3043-3051. | 1.1 | 1 |
| 382 | Fermentative Biohydrogen Modelling and Optimization Research in Light of Miniaturized Parallel Bioreactors. <i>Biotechnology and Biotechnological Equipment</i> , 2013, 27, 3901-3908. | 0.5 | 12 |
| 383 | JAK2 V617F-Mutated Myeloproliferative Neoplasia Developing Five Years after Wild-Type JAK2 Acute Myeloid Leukemia: A Case Report. <i>Acta Haematologica</i> , 2013, 129, 23-25. | 0.7 | 1 |
| 384 | An unknown cause of aortic valve stenosis: polycythemia vera. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 282-285. | 1.0 | 3 |
| 385 | Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. <i>Blood</i> , 2013, 121, 1701-1711. | 0.6 | 78 |
| 386 | Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. <i>American Journal of Hematology</i> , 2013, 88, 141-150. | 2.0 | 107 |
| 387 | Cerebral arteriovenous malformation presenting with polycythemia vera: A case report and literature review. <i>International Journal of Surgery Case Reports</i> , 2013, 4, 813-817. | 0.2 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 388 | Progressive burden of myelofibrosis in untreated patients: Assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study. <i>Leukemia Research</i> , 2013, 37, 911-916. | 0.4 | 32 |
| 389 | Diagnostic value of <i>JAK2 V617F</i> somatic mutation for myeloproliferative cancer in 49,488 individuals from the general population. <i>British Journal of Haematology</i> , 2013, 160, 70-79. | 1.2 | 87 |
| 390 | Concomitant detection of <i>BCR-ABL</i> translocation and <i>JAK2 V617F</i> mutation in five patients with myeloproliferative neoplasm at diagnosis. <i>International Journal of Laboratory Hematology</i> , 2013, 35, e4-5. | 0.7 | 10 |
| 391 | Analysis of the <i>MTHFR</i> (methylenetetrahydrofolate reductase) 677 C>T and 1298 A>G polymorphisms in <i>BCR-ABL</i> negative myeloproliferative neoplasms. <i>International Journal of Laboratory Hematology</i> , 2013, 35, e9-12. | 0.7 | 5 |
| 392 | Polycythemia vera: current pharmacotherapy and future directions. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 609-617. | 0.9 | 17 |
| 393 | Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. <i>Leukemia</i> , 2013, 27, 1953-1958. | 3.3 | 62 |
| 394 | Animal Models of Human Pathology. , 2013, , 537-575. | | 0 |
| 395 | Bleeding and Thrombosis in Hematologic Neoplasia. , 2013, , 1363-1385. | | 1 |
| 396 | A role for reactive oxygen species in <i>JAK2V617F</i> myeloproliferative neoplasm progression. <i>Leukemia</i> , 2013, 27, 2187-2195. | 3.3 | 154 |
| 397 | The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. <i>British Journal of Haematology</i> , 2013, 161, 508-516. | 1.2 | 83 |
| 398 | Myelofibrosis, <i>JAK2</i> inhibitors and erythropoiesis. <i>Leukemia</i> , 2013, 27, 1219-1223. | 3.3 | 12 |
| 399 | Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2013, 88, 507-516. | 2.0 | 106 |
| 400 | Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis. <i>British Journal of Haematology</i> , 2013, 162, 326-335. | 1.2 | 61 |
| 401 | Advances in myelofibrosis: a clinical case approach. <i>Haematologica</i> , 2013, 98, 1499-1509. | 1.7 | 15 |
| 403 | TET2 Mutations in Ph-Negative Myeloproliferative Neoplasms: Identification of Three Novel Mutations and Relationship with Clinical and Laboratory Findings. <i>BioMed Research International</i> , 2013, 2013, 1-5. | 0.9 | 10 |
| 404 | <i>JAK2 V617F</i> Mutation in Iranian Patients with Myeloproliferative Neoplasms: Clinical and Laboratory Findings. <i>Turkish Journal of Medical Sciences</i> , 0, , . | 0.4 | 2 |
| 405 | Development of molecular oncohematology in Ukraine. <i>Biopolymers and Cell</i> , 2013, 29, 277-282. | 0.1 | 2 |
| 407 | Huntingtin-Interacting Protein 1 Phosphorylation by Receptor Tyrosine Kinases. <i>Molecular and Cellular Biology</i> , 2013, 33, 3580-3593. | 1.1 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 408 | If at First You Don't Succeed: Stem-Cell Transplantation for Acute Myeloid Leukemia After First Relapse. <i>Journal of Clinical Oncology</i> , 2013, 31, 1259-1261. | 0.8 | 1 |
| 409 | Idiopathic Myelofibrosis in Children. <i>Journal of Pediatric Hematology/Oncology</i> , 2013, 35, 559-565. | 0.3 | 10 |
| 410 | Concurrent JAK2V617F Mutation and MTHFR C677T Homozygosity in an Adolescent With Polycythemia Vera. <i>Clinical Pediatrics</i> , 2013, 52, 671-674. | 0.4 | 1 |
| 411 | Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. <i>Journal of Hematology and Oncology</i> , 2013, 6, 81. | 6.9 | 89 |
| 413 | Clinical and Laboratory Significance of Defective P2Y12 Pathway Function in Patients with Myeloproliferative Neoplasms: A Pilot Study. <i>Acta Haematologica</i> , 2013, 130, 181-187. | 0.7 | 4 |
| 414 | Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment. <i>British Journal of Haematology</i> , 2013, 163, 295-302. | 1.2 | 25 |
| 415 | Pomalidomide and the growing role of immunomodulatory agents in the treatment of myelofibrosis. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 539-547. | 0.5 | 0 |
| 416 | Expanding the SHOC2 mutation associated phenotype of noonan syndrome with loose anagen hair: Structural brain anomalies and myelofibrosis. <i>American Journal of Medical Genetics, Part A</i> , 2013, 161, 2420-2430. | 0.7 | 38 |
| 417 | The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2013, 88, 355-358. | 2.0 | 57 |
| 418 | Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage. <i>European Journal of Haematology</i> , 2013, 90, 228-236. | 1.1 | 16 |
| 419 | Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F. <i>Journal of Cellular and Molecular Medicine</i> , 2013, 17, 265-276. | 1.6 | 13 |
| 420 | JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms. <i>Jak-stat</i> , 2013, 2, e25025. | 2.2 | 27 |
| 421 | Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. <i>Therapeutic Advances in Hematology</i> , 2013, 4, 15-35. | 1.1 | 85 |
| 422 | Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. <i>Leukemia</i> , 2013, 27, 1874-1881. | 3.3 | 540 |
| 424 | Inherited predisposition to myeloproliferative neoplasms. <i>Therapeutic Advances in Hematology</i> , 2013, 4, 237-253. | 1.1 | 49 |
| 425 | Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFR A rearrangement. <i>Blood</i> , 2013, 122, 3387-3388. | 0.6 | 10 |
| 426 | Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. <i>Haematologica</i> , 2013, 98, 1865-1871. | 1.7 | 143 |
| 430 | Two Cases of Myeloproliferative Neoplasm with a Concurrent JAK2V617F Mutation and BCR/ABL Translocation without Chronic Myelogenous Leukemia Phenotype Acquisition during Hydroxyurea Treatment. <i>Annals of Laboratory Medicine</i> , 2013, 33, 229-232. | 1.2 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 431 | Allelic Expression Imbalance of JAK2 V617F Mutation in BCR-ABL Negative Myeloproliferative Neoplasms. PLoS ONE, 2013, 8, e52518. | 1.1 | 18 |
| 432 | Polymorphism of <i>XRCC1</i> , <i>XRCC3</i> , and <i>XPD</i> Genes and Risk of Chronic Myeloid Leukemia. BioMed Research International, 2014, 2014, 1-9. | 0.9 | 25 |
| 433 | Initial Management of Noncirrhotic Splanchnic Vein Thrombosis: When Is Anticoagulation Enough?. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 207-211. | 0.8 | 3 |
| 434 | A young woman with infertility. , 0, , 90-94. | | 0 |
| 435 | Aid to Enteral Feeding in Critical Care: Algorithm. , 2014, , 1-21. | | 0 |
| 436 | Therapy for myeloproliferative neoplasms: when, which agent, and how?. Hematology American Society of Hematology Education Program, 2014, 2014, 277-286. | 0.9 | 25 |
| 437 | Cerebral Thrombosis and Myeloproliferative Neoplasms. Current Neurology and Neuroscience Reports, 2014, 14, 496. | 2.0 | 32 |
| 438 | Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. Expert Review of Hematology, 2014, 7, 255-264. | 1.0 | 13 |
| 439 | The European Clinical, Molecular, and Pathological (ECMP) Criteria and the 2007/2008 Revisions of the World Health Organization for the Diagnosis, Classification, and Staging of Prefibrotic Myeloproliferative Neoplasms Carrying the JAK2V617F Mutation. Turkish Journal of Haematology, 2014, , 239-254. | 0.2 | 5 |
| 440 | Megakaryocytic Morphology and Clinical Parameters in Essential Thrombocythemia, Polycythemia Vera, and Primary Myelofibrosis With and Without <i>JAK2</i> V617F. Archives of Pathology and Laboratory Medicine, 2014, 138, 1203-1209. | 1.2 | 20 |
| 441 | Ruxolitinib in clinical practice for therapy of myelofibrosis: Single USA center experience following Food and Drug Administration approval. Leukemia and Lymphoma, 2014, 55, 195-197. | 0.6 | 22 |
| 442 | A Multiplex Snapback Primer System for the Enrichment and Detection of <i>JAK2</i> V617F and <i>MPL</i> W515L/K Mutations in Philadelphia-Negative Myeloproliferative Neoplasms. BioMed Research International, 2014, 2014, 1-11. | 0.9 | 6 |
| 445 | A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis. Haematologica, 2014, 99, e5-e7. | 1.7 | 22 |
| 446 | Frequencies, clinical characteristics, and outcome of somatic <i>CALR</i> mutations in <i>JAK2</i> -unmutated essential thrombocythemia. Annals of Hematology, 2014, 93, 2029-2036. | 0.8 | 44 |
| 447 | Myeloid sarcoma with megakaryoblastic differentiation mimicking a sellar tumor. Neuropathology, 2014, 34, 179-184. | 0.7 | 12 |
| 448 | A phase 2 study of ruxolitinib, an oral <i>JAK1</i> and <i>JAK2</i> inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer, 2014, 120, 513-520. | 2.0 | 165 |
| 449 | <i>TET2</i> gene sequencing may be helpful for myeloproliferative neoplasm diagnosis. British Journal of Haematology, 2014, 165, 416-419. | 1.2 | 1 |
| 450 | Genetic association between germline <i>JAK2</i> polymorphisms and myeloproliferative neoplasms in Hong Kong Chinese population: a case-control study. BMC Genetics, 2014, 15, 147. | 2.7 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 451 | Pulmonary hypertension in patients with chronic myeloproliferative neoplasms. <i>Leukemia and Lymphoma</i> , 2014, 55, 223-225. | 0.6 | 18 |
| 453 | Mutation in the First Ig-Like Domain of Kit Leads to JAK2 Activation and Myeloproliferation in Mice. <i>American Journal of Pathology</i> , 2014, 184, 122-132. | 1.9 | 2 |
| 454 | Hes1 upregulation contributes to the development of FIP1L1-PDGFR α -positive leukemia in blast crisis. <i>Experimental Hematology</i> , 2014, 42, 369-379.e3. | 0.2 | 8 |
| 455 | The relationship between factor V Leiden, prothrombin G20210A, and MTHFR mutations and the first major thrombotic episode in polycythemia vera and essential thrombocythemia. <i>Annals of Hematology</i> , 2014, 93, 203-209. | 0.8 | 13 |
| 456 | JAK2 V617F allele burden quantified by real time quantitative polymerase chain reaction and competitive polymerase chain reaction in patients with chronic myeloproliferative neoplasia. <i>Leukemia and Lymphoma</i> , 2014, 55, 128-135. | 0.6 | 4 |
| 457 | Imaging studies in extramedullary hematopoiesis of the spleen. <i>Annals of Hematology</i> , 2014, 93, 347-349. | 0.8 | 2 |
| 459 | JAK2V617F allele burden in patients with myeloproliferative neoplasms. <i>Annals of Hematology</i> , 2014, 93, 791-796. | 0.8 | 15 |
| 461 | Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFR α : roles of Mcl-1 and β -catenin. <i>Molecular Cancer</i> , 2014, 13, 17. | 7.9 | 23 |
| 463 | How common are myeloproliferative neoplasms? A systematic review and meta-analysis. <i>American Journal of Hematology</i> , 2014, 89, 581-587. | 2.0 | 141 |
| 464 | Rethinking the diagnostic criteria of polycythemia vera. <i>Leukemia</i> , 2014, 28, 1191-1195. | 3.3 | 52 |
| 465 | Stroke in essential thrombocythemia. <i>Journal of the Neurological Sciences</i> , 2014, 336, 260-262. | 0.3 | 35 |
| 466 | U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. <i>Leukemia</i> , 2014, 28, 431-433. | 3.3 | 69 |
| 467 | Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. <i>Blood</i> , 2014, 123, 1372-1383. | 0.6 | 69 |
| 468 | <i>ATF7IP</i> as a novel <i>PDGFRB</i> fusion partner in acute lymphoblastic leukaemia in children. <i>British Journal of Haematology</i> , 2014, 165, 836-841. | 1.2 | 30 |
| 469 | External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in a large cohort of Chinese patients. <i>European Journal of Haematology</i> , 2014, 92, 502-509. | 1.1 | 24 |
| 470 | Pathology reporting of bone marrow biopsy in myelofibrosis; application of the Delphi consensus process to the development of a standardised diagnostic report. <i>Journal of Clinical Pathology</i> , 2014, 67, 620-625. | 1.0 | 7 |
| 471 | Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells. <i>Oncogene</i> , 2014, 33, 5379-5390. | 2.6 | 3 |
| 472 | The JAK2 46/1 haplotype (GGCC) in myeloproliferative neoplasms and splanchnic vein thrombosis: a pooled analysis of 26 observational studies. <i>Annals of Hematology</i> , 2014, 93, 1845-1852. | 0.8 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 473 | Considerations and Recommendations for a New Molecular Diagnostic Algorithm for the Myeloproliferative Neoplasms. <i>Genetic Testing and Molecular Biomarkers</i> , 2014, 18, 749-753. | 0.3 | 1 |
| 474 | Prognostication in MF: From CBC to cytogenetics to molecular markers. <i>Best Practice and Research in Clinical Haematology</i> , 2014, 27, 155-164. | 0.7 | 8 |
| 475 | A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms. <i>Best Practice and Research in Clinical Haematology</i> , 2014, 27, 83-93. | 0.7 | 12 |
| 476 | Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options. <i>Annals of Hematology</i> , 2014, 93, 1965-1976. | 0.8 | 34 |
| 477 | Analysis of calreticulin mutations in Chinese patients with essential thrombocythemia: clinical implications in diagnosis, prognosis and treatment. <i>Leukemia</i> , 2014, 28, 1912-1914. | 3.3 | 45 |
| 478 | The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms. <i>Journal of Hematology and Oncology</i> , 2014, 7, 48. | 6.9 | 42 |
| 479 | Primary myelofibrosis: 2014 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2014, 89, 915-925. | 2.0 | 88 |
| 480 | Interferon β gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation. <i>Leukemia Research</i> , 2014, 38, 1177-1183. | 0.4 | 24 |
| 481 | Determination of accuracy of polycythemia vera diagnoses and use of the JAK2V617F test in the diagnostic scheme. <i>Annals of Hematology</i> , 2014, 93, 1467-1472. | 0.8 | 4 |
| 482 | Quality of Life in MPN Comes of Age as a Therapeutic Target. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 324-330. | 1.2 | 15 |
| 484 | Coexistence of Myeloproliferative Neoplasm and Plasma-Cell Dyscrasia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 31-36. | 0.2 | 34 |
| 485 | JAK2 V617F Mutation Status of 232 Patients Diagnosed With Chronic Myeloproliferative Neoplasms. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 525-533. | 0.2 | 10 |
| 486 | Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: A consensus-based SIE, SIES, GITMO position paper. <i>Leukemia Research</i> , 2014, 38, 155-160. | 0.4 | 28 |
| 487 | <i>RCC1</i> Arg194Trp and Arg399Gln polymorphisms are significantly associated with shorter survival in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 365-370. | 0.6 | 20 |
| 488 | JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate. <i>Haematologica</i> , 2014, 99, 1448-1455. | 1.7 | 82 |
| 489 | miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis. <i>Blood</i> , 2014, 124, e21-e32. | 0.6 | 105 |
| 490 | Therapy for myeloproliferative neoplasms: when, which agent, and how?. <i>Blood</i> , 2014, 124, 3529-3537. | 0.6 | 86 |
| 491 | Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer. <i>Case Reports in Oncology</i> , 2014, 7, 316-322. | 0.3 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 492 | Treatment with PF-04449913, an oral smoothed antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. <i>Lancet Haematology</i> , 2015, 2, e339-e346. | 2.2 | 102 |
| 493 | Essential thrombocythaemia in a child of three years. <i>Revista Médica Del Hospital General De México</i> , 2015, 78, 129-134. | 0.0 | 0 |
| 494 | Thrombocytosis in a Patient with Alpha Thalassemia Trait. <i>Laboratory Medicine</i> , 2015, 46, e7-e12. | 0.8 | 1 |
| 495 | The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms. <i>Clinical Case Reports (discontinued)</i> , 2015, 3, 499-503. | 0.2 | 14 |
| 496 | Normal platelet counts mask abnormal thrombopoiesis in patients with chronic myeloid leukemia. <i>Oncology Letters</i> , 2015, 10, 2390-2394. | 0.8 | 9 |
| 497 | Colorectal Liver Metastasis, Primary Gallbladder Carcinoma and Myelofibrosis Present Simultaneously in a Liver Resection Specimen. <i>Case Reports in Gastroenterology</i> , 2015, 9, 335-340. | 0.3 | 0 |
| 499 | Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. <i>Journal of Translational Medicine</i> , 2015, 13, 294. | 1.8 | 36 |
| 500 | BCR-ABL1- positive chronic myeloid leukemia with erythrocytosis presenting as polycythemia vera: a case report. <i>Journal of Medical Case Reports</i> , 2015, 9, 30. | 0.4 | 1 |
| 501 | Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. <i>Haematologica</i> , 2015, 100, 479-488. | 1.7 | 246 |
| 502 | Expression analysis of microRNA-125 in patients with polycythemia vera and essential thrombocythemia and correlation with JAK2 allele burden and laboratory findings. <i>International Journal of Laboratory Hematology</i> , 2015, 37, 661-667. | 0.7 | 6 |
| 503 | Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review. <i>Experimental Hematology and Oncology</i> , 2015, 5, 3. | 2.0 | 18 |
| 504 | Noonan syndrome-like disorder with loose anagen hair: A second case with neuroblastoma. <i>American Journal of Medical Genetics, Part A</i> , 2015, 167, 1902-1907. | 0.7 | 14 |
| 505 | Working environment and myeloproliferative neoplasm: A population-based case-control study following a cluster investigation. <i>American Journal of Industrial Medicine</i> , 2015, 58, 595-604. | 1.0 | 5 |
| 506 | Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms. <i>Liver International</i> , 2015, 35, 2042-2049. | 1.9 | 35 |
| 508 | Whole-exome sequencing and genome-wide methylation analyses identify novel disease associated mutations and methylation patterns in idiopathic hypereosinophilic syndrome. <i>Oncotarget</i> , 2015, 6, 40588-40597. | 0.8 | 14 |
| 509 | Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms. <i>Journal of Blood Medicine</i> , 2015, 6, 157. | 0.7 | 18 |
| 510 | A Case of Essential Thrombocythemia in a Patient with Ankylosing Spondylitis Concomitantly Treated with Adalimumab. <i>Journal of Rheumatic Diseases</i> , 2015, 22, 51. | 0.4 | 0 |
| 511 | Guidelines for the management of myeloproliferative neoplasms. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 771-788. | 0.7 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 512 | Atypical CML with massive splenic infarct: an extremely rare presentation. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015212821-bcr2015212821. | 0.2 | 1 |
| 513 | Risk-Reducing Genetic Variant of Wilms Tumor 1 Gene rs16754 in Korean Patients With BCR-ABL1-Negative Myeloproliferative Neoplasm. <i>Annals of Laboratory Medicine</i> , 2015, 35, 348-351. | 1.2 | 1 |
| 514 | JAK2V617F Drives Mcl-1 Expression and Sensitizes Hematologic Cell Lines to Dual Inhibition of JAK2 and Bcl-xL. <i>PLoS ONE</i> , 2015, 10, e0114363. | 1.1 | 22 |
| 515 | Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells. <i>PLoS ONE</i> , 2015, 10, e0140445. | 1.1 | 20 |
| 516 | Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms. <i>Mediators of Inflammation</i> , 2015, 2015, 1-17. | 1.4 | 40 |
| 517 | Aetiological factors of Budd-Chiari syndrome in Algeria. <i>World Journal of Hepatology</i> , 2015, 7, 903. | 0.8 | 20 |
| 518 | Bone morbidity in chronic myeloproliferative neoplasms. <i>Expert Review of Hematology</i> , 2015, 8, 447-456. | 1.0 | 8 |
| 519 | A Novel Hemoglobin Variant Found on the β 1 Chain: Hb KSVGH (HBA1): Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 462 Td (p.Lys572Gln). <i>PLoS ONE</i> , 2015, 10, e0140445. | 0.4 | 3 |
| 520 | Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis. <i>Leukemia Research</i> , 2015, 39, 684-688. | 0.4 | 4 |
| 521 | Ion concentration polarization on paper-based microfluidic devices and its application to preconcentrate dilute sample solutions. <i>Biomicrofluidics</i> , 2015, 9, 014122. | 1.2 | 63 |
| 522 | Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib. <i>Blood Cancer Journal</i> , 2015, 5, e351-e351. | 2.8 | 30 |
| 523 | Ischemic Stroke with Essential Thrombocythemia: A Case Series. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2015, 24, 890-893. | 0.7 | 25 |
| 524 | The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms. <i>Thrombosis Research</i> , 2015, 135, 272-280. | 0.8 | 61 |
| 525 | Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 1005-11. | 1.4 | 7 |
| 526 | JAK2 V617F, MPL, and CALR Mutations in Essential Thrombocythaemia and Major Thrombotic Complications: A Single-Institute Retrospective Analysis. <i>Pathology and Oncology Research</i> , 2015, 21, 751-758. | 0.9 | 11 |
| 527 | Ruxolitinib: A Review of Its Use in Patients with Myelofibrosis. <i>Drugs</i> , 2015, 75, 297-308. | 4.9 | 60 |
| 528 | Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk stratification and management. <i>American Journal of Hematology</i> , 2015, 90, 162-173. | 2.0 | 213 |
| 529 | Novel and emerging therapies for the treatment of polycythemia vera. <i>Expert Review of Hematology</i> , 2015, 8, 101-113. | 1.0 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 530 | IPSET-Thrombosis Better Identifies Thrombosis-Free Survival: A Turkish Cohort. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e101-e104. | 0.2 | 4 |
| 531 | High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms. <i>European Journal of Internal Medicine</i> , 2015, 26, 344-347. | 1.0 | 49 |
| 532 | Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden. <i>Thrombosis Research</i> , 2015, 135, 846-851. | 0.8 | 24 |
| 534 | Essential thrombocythemia with <i>Mpl W515 K</i> mutation in a child presenting with Budd-Chiari syndrome. <i>Platelets</i> , 2015, 26, 805-808. | 1.1 | 7 |
| 536 | Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia. <i>Internal and Emergency Medicine</i> , 2015, 10, 451-460. | 1.0 | 7 |
| 537 | MicroRNA Expression Analysis in Patients with Primary Myelofibrosis, Polycythemia vera and Essential Thrombocythemia. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2015, 31, 416-425. | 0.3 | 8 |
| 538 | <i>CALR</i> versus <i>JAK2</i> mutated essential thrombocythaemia – a report on 141 patients. <i>British Journal of Haematology</i> , 2015, 168, 151-153. | 1.2 | 15 |
| 539 | Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. <i>Leukemia</i> , 2015, 29, 1344-1349. | 3.3 | 62 |
| 540 | Advances in Smartphone-Based Point-of-Care Diagnostics. <i>Proceedings of the IEEE</i> , 2015, 103, 236-247. | 16.4 | 169 |
| 541 | Nilotinib Does Not Alter the Secretory Functions of Carotid Artery Endothelial Cells in a Prothrombotic or Antithrombotic Fashion. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2015, 21, 678-683. | 0.7 | 10 |
| 542 | Essential Thrombocythemia: The Dermatologic Point of View. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 739-747. | 0.2 | 21 |
| 543 | Management of side effects of BCR/ABL-negative chronic myeloproliferative neoplasm therapies. Focus on anagrelide. <i>Expert Review of Hematology</i> , 2015, 8, 819-835. | 1.0 | 0 |
| 544 | The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis. <i>International Journal of Hematology</i> , 2015, 102, 170-180. | 0.7 | 12 |
| 546 | Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 2047-2060. | 1.2 | 50 |
| 548 | Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib. <i>BMC Nephrology</i> , 2015, 16, 121. | 0.8 | 11 |
| 549 | Recombinant interferon- γ in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. <i>Modern Pathology</i> , 2015, 28, 1315-1323. | 2.9 | 49 |
| 550 | Myeloproliferative neoplasms in children. <i>Journal of Hematopathology</i> , 2015, 8, 143-157. | 0.2 | 45 |
| 551 | Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study. <i>Leukemia Research</i> , 2015, 39, 592-598. | 0.4 | 21 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 552 | Low incidence of CALR gene mutations in patients with cerebral venous thrombosis without overt chronic myeloproliferative neoplasm. <i>Thrombosis Research</i> , 2015, 136, 839-840. | 0.8 | 5 |
| 553 | Methylenetetrahydrofolate reductase 677 C> T polymorphism is associated with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 1172-1174. | 0.6 | 1 |
| 554 | The JAK2 46/1 haplotype does not predispose to CALR-mutated myeloproliferative neoplasms. <i>Annals of Hematology</i> , 2015, 94, 789-794. | 0.8 | 9 |
| 555 | Erlotinib is not effective in patients with JAK2V617F-positive polycythemia vera. <i>Annals of Hematology</i> , 2015, 94, 717-719. | 0.8 | 1 |
| 556 | Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis. <i>Journal of Hepatology</i> , 2015, 62, 72-74. | 1.8 | 72 |
| 557 | The Implication of Cancer Progenitor Cells and the Role of Epigenetics in the Development of Novel Therapeutic Strategies for Chronic Myeloid Leukemia. <i>Antioxidants and Redox Signaling</i> , 2015, 22, 1425-1462. | 2.5 | 9 |
| 558 | When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm. , 0, , 22-36. | | 0 |
| 559 | The Danish National Chronic Myeloid Neoplasia Registry. <i>Clinical Epidemiology</i> , 2016, Volume 8, 567-572. | 1.5 | 11 |
| 560 | Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea. <i>Journal of Korean Medical Science</i> , 2016, 31, 1579. | 1.1 | 24 |
| 561 | Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations. <i>Journal of Blood Medicine</i> , 2016, Volume 7, 205-215. | 0.7 | 6 |
| 562 | Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e324-e335. | 1.8 | 8 |
| 563 | From Six Gene Polymorphisms of the Antioxidant System, Only GPX Pro198Leu and GSTP1 Ile105Val Modulate the Risk of Acute Myeloid Leukemia. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-10. | 1.9 | 25 |
| 564 | Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4937-4957. | 1.0 | 13 |
| 565 | Correlative study between the JAK2V617F mutation and thrombosis in patients with myeloproliferative neoplasm. <i>Genetics and Molecular Research</i> , 2016, 15, . | 0.3 | 0 |
| 566 | Ruxolitinib: a targeted treatment option for patients with polycythemia vera. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2016, 6, 7. | 1.2 | 0 |
| 567 | Recent advances in understanding myelofibrosis and essential thrombocythemia. <i>F1000Research</i> , 2016, 5, 700. | 0.8 | 39 |
| 568 | Activation of the tissue factor-dependent extrinsic pathway and its relation to JAK2 V617F mutation status in patients with essential thrombocythemia. <i>Blood Coagulation and Fibrinolysis</i> , 2016, 27, 817-821. | 0.5 | 4 |
| 569 | Treatment of Myelofibrosis. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 51-61. | 1.0 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 570 | Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase. <i>European Journal of Haematology</i> , 2016, 96, 643-649. | 1.1 | 19 |
| 571 | A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells. <i>Blood Cancer Journal</i> , 2016, 6, e439-e439. | 2.8 | 16 |
| 572 | The evolution and clinical relevance of prognostic classification systems in myelofibrosis. <i>Cancer</i> , 2016, 122, 681-692. | 2.0 | 17 |
| 573 | Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera. <i>European Journal of Haematology</i> , 2016, 96, 285-290. | 1.1 | 17 |
| 574 | <i>TERT</i> rs2736100 A>C SNP and <i>JAK2</i> 46/1 haplotype significantly contribute to the occurrence of <i>JAK2</i> V617F and <i>CALR</i> mutated myeloproliferative neoplasms – a multicentric study on 529 patients. <i>British Journal of Haematology</i> , 2016, 174, 218-226. | 1.2 | 32 |
| 575 | High frequency of <i>JAK2</i> exon 12 mutations in Korean patients with polycythemia vera: novel mutations and clinical significance. <i>Journal of Clinical Pathology</i> , 2016, 69, 737-741. | 1.0 | 8 |
| 576 | Genetic analysis of five children with essential thrombocytosis identified mutations in cancer-associated genes with roles in transcriptional regulation. <i>Haematologica</i> , 2016, 101, e237-e239. | 1.7 | 17 |
| 577 | Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. <i>Haematologica</i> , 2016, 101, 821-829. | 1.7 | 140 |
| 578 | Protocolo diagnóstico de la poliglobulia. <i>Medicine</i> , 2016, 12, 1180-1183. | 0.0 | 0 |
| 579 | Generation of the <i>Fip1l1</i> - <i>Pdgfra</i> fusion gene using CRISPR/Cas genome editing. <i>Leukemia</i> , 2016, 30, 1913-1916. | 3.3 | 9 |
| 580 | The expression of Death Inducer-Obliterator (DIDO) variants in Myeloproliferative Neoplasms. <i>Blood Cells, Molecules, and Diseases</i> , 2016, 59, 25-30. | 0.6 | 7 |
| 581 | Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring <i>CALR</i> , <i>JAK2</i> V617F, <i>JAK2</i> Ex12del, and <i>MPLW515L/K</i> mutations. <i>Leukemia Research</i> , 2016, 40, 68-76. | 0.4 | 13 |
| 582 | A case of myeloid neoplasm with <i>FIP1L1</i> - <i>PDGFRA</i> rearrangement without marked peripheral blood eosinophilia. <i>Pharmacogenomics</i> , 2016, 17, 99-102. | 0.6 | 0 |
| 583 | Allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A single center experience. <i>Annals of Hematology</i> , 2016, 95, 973-983. | 0.8 | 2 |
| 584 | High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. <i>Leukemia</i> , 2016, 30, 2032-2038. | 3.3 | 75 |
| 585 | A portable sample concentrator on paper-based microfluidic devices. <i>Microfluidics and Nanofluidics</i> , 2016, 20, 1. | 1.0 | 25 |
| 586 | Genomic landscape of megakaryopoiesis and platelet function defects. <i>Blood</i> , 2016, 127, 1249-1259. | 0.6 | 53 |
| 587 | Classification of Mastocytosis. , 2016, , 197-204. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 588 | Pregnancy outcomes in myeloproliferative neoplasms: <sc>UK</sc> prospective cohort study. British Journal of Haematology, 2016, 175, 31-36. | 1.2 | 65 |
| 589 | Epidemiología de la leucemia mieloide crónica en España y sus posibles implicaciones terapéuticas. Revista Clínica Española, 2016, 216, 311-312. | 0.2 | 1 |
| 591 | Laboratory Investigation of Myeloproliferative Neoplasms (MPNs). American Journal of Clinical Pathology, 2016, 146, 408-422. | 0.4 | 30 |
| 592 | The germline mutations of the <i>CHEK2</i> gene are associated with an increased risk of polycythaemia vera. British Journal of Haematology, 2016, 173, 150-152. | 1.2 | 9 |
| 593 | Thrombosis in thrombocytopenic Ph–myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide. European Journal of Haematology, 2016, 96, 98-106. | 1.1 | 21 |
| 594 | Prognosis of Primary Myelofibrosis in the Genomic Era. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S105-S113. | 0.2 | 12 |
| 595 | The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer. Journal of Molecular Diagnostics, 2016, 18, 605-619. | 1.2 | 55 |
| 597 | Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. Blood Cancer Journal, 2016, 6, e493-e493. | 2.8 | 80 |
| 598 | Absence of CALR mutation among a cohort of 394 unselected patients with a first episode of unprovoked venous thromboembolism. Thrombosis and Haemostasis, 2016, 115, 225-226. | 1.8 | 6 |
| 599 | JAK2 V617F mutation, multiple hematologic and non-hematologic processes: an association?. Biomarker Research, 2016, 4, 19. | 2.8 | 2 |
| 600 | Acute Lymphoblastic Leukemia in the Course of Polycythemia Vera: A Case Report and Review of Literature. Indian Journal of Hematology and Blood Transfusion, 2016, 32, 50-55. | 0.3 | 3 |
| 601 | Diversities of Calreticulin Gene Mutations in Macedonian Patients With Essential Thrombocythemia. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 477-481. | 0.2 | 2 |
| 602 | Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia, 2016, 30, 1701-1707. | 3.3 | 393 |
| 603 | Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia. Annals of Hematology, 2016, 95, 1197-1200. | 0.8 | 28 |
| 604 | Distribution and features of hematological malignancies in Eastern Morocco: a retrospective multicenter study over 5–years. BMC Cancer, 2016, 16, 159. | 1.1 | 21 |
| 605 | Serum Angiopoietin Levels are Different in Acute and Chronic Myeloid Neoplasms: Angiopoietins do not only Regulate Tumor Angiogenesis. Indian Journal of Hematology and Blood Transfusion, 2016, 32, 162-167. | 0.3 | 7 |
| 606 | Myelodysplastic syndrome with del (5q) and JAK2V617F mutation transformed to acute myeloid leukaemia with complex karyotype. Annals of Hematology, 2016, 95, 525-527. | 0.8 | 2 |
| 607 | Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. Journal of Clinical Oncology, 2016, 34, 151-159. | 0.8 | 56 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 608 | New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms. <i>Current Opinion in Hematology</i> , 2016, 23, 137-143. | 1.2 | 23 |
| 609 | The prevalence of CALR mutations in a cohort of patients with myeloproliferative neoplasms. <i>International Journal of Laboratory Hematology</i> , 2016, 38, 102-106. | 0.7 | 3 |
| 610 | A case of myeloproliferative neoplasm with a normal complete blood cell count: A novel problem of the JAK2 era. <i>Oncology Letters</i> , 2016, 11, 2134-2136. | 0.8 | 4 |
| 611 | Clinicopathologic features and prognostic indicators in Chinese patients with myelofibrosis. <i>Hematology</i> , 2016, 21, 10-18. | 0.7 | 3 |
| 612 | Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method. <i>Annals of Hematology</i> , 2016, 95, 719-732. | 0.8 | 5 |
| 613 | Distinct molecular abnormalities underlie unique clinical features of essential thrombocythemia in children. <i>Leukemia</i> , 2016, 30, 746-749. | 3.3 | 19 |
| 614 | The glucocorticoid receptor A3669G SNP is not associated with polycythemia vera, essential thrombocythemia or primary myelofibrosis. <i>Leukemia and Lymphoma</i> , 2016, 57, 209-211. | 0.6 | 1 |
| 615 | Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera. <i>Leukemia and Lymphoma</i> , 2016, 57, 348-354. | 0.6 | 40 |
| 616 | Ruxolitinib â€œ better prognostic impact in low-intermediate 1 risk score: evaluation of the â€œrete ematologica puglieseâ€™ (REP) in primary and secondary myelofibrosis. <i>Leukemia and Lymphoma</i> , 2017, 58, 138-144. | 0.6 | 6 |
| 617 | Oxidative status in treatment-naïve essential thrombocythemia: a pilot study in a single center. <i>Hematological Oncology</i> , 2017, 35, 335-340. | 0.8 | 0 |
| 618 | The clonal origins of leukemic progression of myelodysplasia. <i>Leukemia</i> , 2017, 31, 1928-1935. | 3.3 | 41 |
| 620 | The role of the extracellular matrix in primary myelofibrosis. <i>Blood Cancer Journal</i> , 2017, 7, e525-e525. | 2.8 | 41 |
| 622 | Observational retrospective study of vascular modulator changes during treatment in essential thrombocythemia. <i>Translational Research</i> , 2017, 184, 21-34. | 2.2 | 16 |
| 623 | Platelet Counting and Measurement of Platelet Dimensions. , 2017, , 571-587. | | 4 |
| 624 | Experience with ruxolitinib in the treatment of polycythaemia vera. <i>Therapeutic Advances in Hematology</i> , 2017, 8, 139-151. | 1.1 | 11 |
| 625 | Megakaryocytes in Myeloproliferative Neoplasms Have Unique Somatic Mutations. <i>American Journal of Pathology</i> , 2017, 187, 1512-1522. | 1.9 | 12 |
| 626 | Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 479-487. | 0.2 | 21 |
| 627 | Magnetic sensing platform technologies for biomedical applications. <i>Lab on A Chip</i> , 2017, 17, 1884-1912. | 3.1 | 99 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 628 | Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. <i>Annals of Hematology</i> , 2017, 96, 1113-1120. | 0.8 | 68 |
| 629 | Modeling myeloproliferative neoplasms: From mutations to mouse models and back again. <i>Blood Reviews</i> , 2017, 31, 139-150. | 2.8 | 9 |
| 630 | A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. <i>Leukemia Research</i> , 2017, 60, 11-17. | 0.4 | 35 |
| 631 | Leukemic transformation in patients with myeloproliferative neoplasms: a population-based retrospective study. <i>Future Oncology</i> , 2017, 13, 1239-1246. | 1.1 | 0 |
| 632 | pSTAT5 and ERK exhibit different expression in myeloproliferative neoplasms. <i>Oncology Reports</i> , 2017, 37, 2295-2307. | 1.2 | 4 |
| 633 | Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis. <i>American Journal of Hematology</i> , 2017, 92, 555-561. | 2.0 | 12 |
| 636 | Noninvasive imaging of retinal blood flow in myeloproliferative neoplasms. <i>Acta Ophthalmologica</i> , 2017, 95, 146-152. | 0.6 | 21 |
| 637 | Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease. <i>Therapeutic Advances in Hematology</i> , 2017, 8, 107-118. | 1.1 | 40 |
| 638 | Kinase signaling and targeted therapy for primary myelofibrosis. <i>Experimental Hematology</i> , 2017, 48, 32-38. | 0.2 | 8 |
| 639 | Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population. <i>Biomedical Reports</i> , 2017, 7, 370-376. | 0.9 | 10 |
| 640 | A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia. <i>Leukemia Research</i> , 2017, 61, 89-95. | 0.4 | 38 |
| 641 | A portable microfluidic platform for rapid molecular diagnostic testing of patients with myeloproliferative neoplasms. <i>Scientific Reports</i> , 2017, 7, 8596. | 1.6 | 6 |
| 642 | Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?. <i>Cerebrovascular Diseases</i> , 2017, 44, 97-104. | 0.8 | 16 |
| 643 | DNA repair genes polymorphisms and genetic susceptibility to Philadelphia-negative myeloproliferative neoplasms in a Portuguese population: The role of base excision repair genes polymorphisms. <i>Oncology Letters</i> , 2017, 13, 4641-4650. | 0.8 | 8 |
| 644 | Clinical significance of circulating microparticles in Philadelphia-negative myeloproliferative neoplasms. <i>Oncology Letters</i> , 2017, 14, 2531-2536. | 0.8 | 36 |
| 645 | CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles. <i>Blood Cancer Journal</i> , 2017, 7, 638. | 2.8 | 27 |
| 646 | Benefits and Risks of Antithrombotic Therapy in Essential Thrombocythemia. <i>Annals of Internal Medicine</i> , 2017, 167, 170. | 2.0 | 42 |
| 647 | The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). <i>British Journal of Haematology</i> , 2017, 176, 76-85. | 1.2 | 69 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 648 | Analysis of thrombosis and bleeding complications in patients with polycythemia vera: a Turkish retrospective study. <i>International Journal of Hematology</i> , 2017, 105, 70-78. | 0.7 | 8 |
| 649 | The promise of Janus kinase inhibitors in the treatment of hematological malignancies. <i>Cytokine</i> , 2017, 98, 33-41. | 1.4 | 35 |
| 650 | CALR gene mutational profile in myeloproliferative neoplasms with non-mutated JAK2 in Moroccan patients: A case series and germline in-frame deletion. <i>Current Research in Translational Medicine</i> , 2017, 65, 15-19. | 1.2 | 4 |
| 651 | Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. <i>Leukemia and Lymphoma</i> , 2017, 58, 866-871. | 0.6 | 4 |
| 652 | Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway. <i>European Journal of Haematology</i> , 2017, 98, 85-93. | 1.1 | 36 |
| 653 | Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin. <i>European Journal of Haematology</i> , 2017, 98, 106-111. | 1.1 | 12 |
| 654 | Peripheral and bone marrow CD34 ⁺ cell levels on chronic myeloproliferative disease. <i>Hematology</i> , 2017, 22, 74-80. | 0.7 | 3 |
| 655 | Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2017, 92, 187-195. | 2.0 | 41 |
| 656 | JAK2, MPL, and CALR mutations in Chinese Han patients with essential thrombocythemia. <i>Hematology</i> , 2017, 22, 145-148. | 0.7 | 7 |
| 657 | Approach to the Diagnosis and Classification of Blood Cell Disorders. , 2017, , 497-510. | | 9 |
| 658 | Molecular Testing in Myeloproliferative Neoplasms. , 2017, , 435-447. | | 0 |
| 659 | Predicting pathogenic genes for primary myelofibrosis based on a systemâ€network approach. <i>Molecular Medicine Reports</i> , 2018, 17, 186-192. | 1.1 | 1 |
| 660 | The relevance of a low <i>JAK2</i> V617F allele burden in clinical practice: a monocentric study. <i>Oncotarget</i> , 2017, 8, 37239-37249. | 0.8 | 18 |
| 661 | Mean platelet volume and risk of thrombotic and bleeding complications in patients with Philadelphia chromosome negative myeloproliferative neoplasms. <i>Blood Coagulation and Fibrinolysis</i> , 2018, 29, 288-293. | 0.5 | 6 |
| 662 | Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. <i>Seminars in Hematology</i> , 2018, 55, 215-222. | 1.8 | 13 |
| 663 | Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. <i>Leukemia</i> , 2018, 32, 1034-1037. | 3.3 | 56 |
| 664 | Disease and treatment characteristics of polycythemia vera patients in Belgium: Results from a scientific survey. <i>European Journal of Haematology</i> , 2018, 100, 361-366. | 1.1 | 5 |
| 665 | The role of extracellular matrix stiffness in megakaryocyte and platelet development and function. <i>American Journal of Hematology</i> , 2018, 93, 430-441. | 2.0 | 45 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 666 | <i>MECOM</i>, <i>HBS1L</i>MYB</i>, <i>THRB</i>CRARB, JAK2</i>, and <i>TERT</i> polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients. <i>American Journal of Hematology</i> , 2018, 93, 100-106. | 2.0 | 30 |
| 667 | High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocythemia carrying V617F mutation. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 106-113. | 1.0 | 14 |
| 668 | The Relative Bioavailability, Food Effect, and Drug Interaction With Omeprazole of Momelotinib Tablet Formulation in Healthy Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 277-286. | 0.8 | 7 |
| 669 | Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. <i>International Journal of Hematology</i> , 2018, 107, 83-91. | 0.7 | 9 |
| 670 | Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. <i>Annals of Hematology</i> , 2018, 97, 435-441. | 0.8 | 95 |
| 671 | Essential thrombocythemia during treatment of acute myeloid leukemia with JAK2 V617F mutation. <i>Medicine (United States)</i> , 2018, 97, e11331. | 0.4 | 3 |
| 672 | Myeloproliferative and "Overlap" Myelodysplastic/Myeloproliferative Neoplasms. , 2018, , 488-538.e4. | | 5 |
| 673 | Retroperitoneal extramedullary plasmacytoma. <i>Medicine (United States)</i> , 2018, 97, e13281. | 0.4 | 11 |
| 674 | Deficiency of the Endocytic Protein Hip1 Leads to Decreased <i>Gdp3</i> Expression, Low Phosphocholine, and Kypholordosis. <i>Molecular and Cellular Biology</i> , 2018, 38, . | 1.1 | 5 |
| 675 | Increased cardiovascular comorbidities in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia presenting with systemic inflammatory and autoimmune manifestations. <i>Seminars in Hematology</i> , 2018, 55, 242-247. | 1.8 | 20 |
| 676 | Safety and efficacy of combination therapy of interferon- α 2 and ruxolitinib in polycythemia vera and myelofibrosis. <i>Cancer Medicine</i> , 2018, 7, 3571-3581. | 1.3 | 38 |
| 677 | Chronic myelogenous leukemia presenting with central nervous system infiltration, successfully treated with central nervous system-directed chemotherapy followed by allogeneic stem cell transplantation. <i>International Journal of Hematology</i> , 2018, 108, 640-646. | 0.7 | 9 |
| 678 | The comorbidity of acute ischemic stroke and splenic infarction resulting from essential thrombocythemia. <i>Neurological Sciences</i> , 2018, 39, 1787-1790. | 0.9 | 5 |
| 679 | Diagnosis of Myeloproliferative Neoplasms: Current Perspectives from Recent Research. , 2019, , 211-230. | | 0 |
| 680 | JAK2, 46/1 haplotype and chronic myelogenous leukemia: diagnostic and therapeutic potential. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 58, e24-e26. | 1.4 | 0 |
| 681 | Cell Adhesion by Integrins. <i>Physiological Reviews</i> , 2019, 99, 1655-1699. | 13.1 | 250 |
| 682 | Update on mutations in the HIF: EPO pathway and their role in erythrocytosis. <i>Blood Reviews</i> , 2019, 37, 100590. | 2.8 | 50 |
| 683 | Piezoelectric Microchip for Cell Lysis through Cell "Microparticle Collision within a Microdroplet Driven by Surface Acoustic Wave Oscillation. <i>Small</i> , 2019, 15, e1804593. | 5.2 | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 684 | Neutropenia and leukemia development: genetic risk factors and prognosis. <i>Leukemia and Lymphoma</i> , 2019, 60, 3363-3374. | 0.6 | 9 |
| 685 | Genomics and Precision Medicine: Molecular Diagnostics Innovations Shaping the Future of Healthcare in Qatar. <i>Advances in Public Health</i> , 2019, 2019, 1-11. | 0.7 | 11 |
| 686 | Challenges in the diagnosis and treatment of secondary acute myeloid leukemia. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 6-13. | 2.0 | 16 |
| 687 | Review article: a multidisciplinary approach to the diagnosis and management of Budd-Chiari syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 840-863. | 1.9 | 33 |
| 688 | A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia – the TEAM – 0 trial. <i>British Journal of Haematology</i> , 2019, 185, 691-700. | 1.2 | 4 |
| 689 | Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia. <i>Blood Advances</i> , 2019, 3, 339-349. | 2.5 | 36 |
| 690 | A rare cause of acute coronary syndromes in young adults – myeloproliferative neoplasms: A case series. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2019, 38, 613-617. | 0.2 | 0 |
| 691 | A rare cause of acute coronary syndromes in young adults – myeloproliferative neoplasms: A case series. <i>Revista Portuguesa De Cardiologia</i> , 2019, 38, 613-617. | 0.2 | 4 |
| 692 | Cementless bipolar hemiarthroplasty in a patient with PMF: a case report. <i>Journal of Surgical Case Reports</i> , 2019, 2019, rjz274. | 0.2 | 0 |
| 693 | Clinical Exome Sequencing unravels new disease-causing mutations in the myeloproliferative neoplasms: A pilot study in patients from the state of Qatar. <i>Gene</i> , 2019, 689, 34-42. | 1.0 | 18 |
| 694 | Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms. <i>Haematologica</i> , 2019, 104, 937-946. | 1.7 | 5 |
| 695 | The Role of Caspase Genes Polymorphisms in Genetic Susceptibility to Philadelphia-Negative Myeloproliferative Neoplasms in a Portuguese Population. <i>Pathology and Oncology Research</i> , 2019, 25, 961-969. | 0.9 | 6 |
| 696 | Evaluation of platelet function in essential thrombocythemia under different analytical conditions. <i>Platelets</i> , 2020, 31, 179-186. | 1.1 | 12 |
| 697 | Altered expression and functional role of ion channels in leukemia: bench to bedside. <i>Clinical and Translational Oncology</i> , 2020, 22, 283-293. | 1.2 | 10 |
| 698 | A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post-APV/ET MF. <i>Leukemia Research</i> , 2020, 88, 106272. | 0.4 | 25 |
| 699 | A Case of Acquired von Willebrand Disease Secondary to Myeloproliferative Neoplasm. <i>Case Reports in Oncology</i> , 2020, 13, 733-737. | 0.3 | 4 |
| 700 | Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms. <i>Annals of Hematology</i> , 2020, 100, 2015-2022. | 0.8 | 16 |
| 701 | Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms. <i>Haematologica</i> , 2020, 105, e91-e94. | 1.7 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 702 | Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia. <i>Haematologica</i> , 2021, 106, 2215-2223. | 1.7 | 12 |
| 703 | Single-cell mutation analysis of clonal evolution in myeloid malignancies. <i>Nature</i> , 2020, 587, 477-482. | 13.7 | 304 |
| 704 | The advantages and risks of ruxolitinib for the treatment of polycythemia vera. <i>Expert Review of Hematology</i> , 2020, 13, 1067-1072. | 1.0 | 8 |
| 705 | The impact of CYP2D6*4 and GSTP1 Ile105Val polymorphisms on the susceptibility to develop BCR-ABL1 negative myeloproliferative neoplasms. <i>Molecular Biology Reports</i> , 2020, 47, 7413-7420. | 1.0 | 1 |
| 706 | Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis. <i>Blood Advances</i> , 2020, 4, 6353-6363. | 2.5 | 36 |
| 707 | Co-existence of myeloproliferative neoplasias and β^2 -thalassemia with IVS-2-654 mutation—a case report. <i>Translational Cancer Research</i> , 2020, 9, 2069-2073. | 0.4 | 2 |
| 708 | Contemporary Classification and Diagnostic Evaluation of Hypereosinophilia. <i>American Journal of Clinical Pathology</i> , 2020, 154, 305-318. | 0.4 | 10 |
| 709 | Serum Has Higher Proportion of Janus Kinase 2 V617F Mutation Compared to Paired EDTA-Whole Blood Sample: A Model for Somatic Mutation Quantification Using qPCR and the 2- β - β -Cq Method. <i>Diagnostics</i> , 2020, 10, 153. | 1.3 | 8 |
| 710 | Myelofibrosis biology and contemporary management. <i>British Journal of Haematology</i> , 2020, 191, 152-170. | 1.2 | 43 |
| 711 | Essential thrombocythemia A retrospective case series. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28183. | 0.8 | 2 |
| 712 | Association of mast cells and bone marrow reticulin fibrosis in patients with bcr-abl negative chronic myeloproliferative neoplasms. <i>Blood Cells, Molecules, and Diseases</i> , 2020, 82, 102420. | 0.6 | 3 |
| 713 | Real-world non-interventional long-term post-approval safety study of ruxolitinib in myelofibrosis. <i>British Journal of Haematology</i> , 2020, 191, 764-774. | 1.2 | 20 |
| 714 | JAK2V617F, CALR and MPL515L/K mutations and plateletcrit in essential thrombocythemia: A single centre's experience. <i>International Journal of Clinical Practice</i> , 2021, 75, e13834. | 0.8 | 1 |
| 715 | Polycythaemia vera: molecular genetics, diagnostics and therapeutics. <i>Vox Sanguinis</i> , 2021, 116, 617-627. | 0.7 | 5 |
| 716 | A Broad Overview of Signaling in Ph-Negative Classic Myeloproliferative Neoplasms. <i>Cancers</i> , 2021, 13, 984. | 1.7 | 17 |
| 717 | Tumor models in various <i>Drosophila</i> tissues. <i>WIREs Mechanisms of Disease</i> , 2021, 13, e1525. | 1.5 | 13 |
| 718 | Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis. <i>American Journal of Hematology</i> , 2021, 96, 749-754. | 2.0 | 3 |
| 719 | Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 413-423. | 0.7 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 720 | Rare case of plasmablastic myeloma diagnosed on lung biopsy. <i>BMJ Case Reports</i> , 2021, 14, e240998. | 0.2 | 2 |
| 721 | Triple-Negative Essential Thrombocythemia: Clinical-Pathological and Molecular Features. A Single-Center Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 637116. | 1.3 | 15 |
| 722 | Genome editing to model and reverse a prevalent mutation associated with myeloproliferative neoplasms. <i>PLoS ONE</i> , 2021, 16, e0247858. | 1.1 | 4 |
| 723 | Low JAK2 V617F Allele Burden in Ph-Negative Chronic Myeloproliferative Neoplasms Is Associated with Additional CALR or MPL Gene Mutations. <i>Genes</i> , 2021, 12, 559. | 1.0 | 3 |
| 724 | Clinical Characteristics and Management of Cerebral Venous Sinus Thrombosis in Patients with Essential Thrombocythemia. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 1195-1206. | 1.0 | 6 |
| 725 | PPAR γ agonists promote the resolution of myelofibrosis in preclinical models. <i>Journal of Clinical Investigation</i> , 2021, 131, . | 3.9 | 4 |
| 726 | The Prevalence of TET2 Gene Mutations in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms (MPN): A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 3078. | 1.7 | 10 |
| 727 | IRF4 and IRF8 expression are associated with clinical phenotype and clinico-hematological response to hydroxyurea in essential thrombocythemia. <i>Frontiers of Medicine</i> , 2022, 16, 403-415. | 1.5 | 3 |
| 728 | Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry. <i>Cancers</i> , 2021, 13, 4086. | 1.7 | 17 |
| 729 | Eosinophilic Myocarditis. <i>Cardiology in Review</i> , 2021, Publish Ahead of Print, . | 0.6 | 0 |
| 730 | Comparison of the effects between MPL and JAK2V617F on thrombosis and peripheral blood cell counts in patients with essential thrombocythemia: a meta-analysis. <i>Annals of Hematology</i> , 2021, 100, 2699-2706. | 0.8 | 6 |
| 731 | Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 1411-1421. | 0.6 | 8 |
| 732 | Analysis of Mutational Hotspots in Routinely Processed Bone Marrow Trepines by Pyrosequencing [®] . <i>Methods in Molecular Biology</i> , 2015, 1315, 103-114. | 0.4 | 11 |
| 735 | Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the "Ph ⁻ negative Myeloproliferative Neoplasms Latium Group". <i>European Journal of Haematology</i> , 2020, 105, 335-343. | 1.1 | 8 |
| 736 | Efficacy of ALK5 inhibition in myelofibrosis. <i>JCI Insight</i> , 2017, 2, e90932. | 2.3 | 37 |
| 737 | Systemic Mastocytosis in Association with Small Lymphocytic Lymphoma. <i>American Journal of Case Reports</i> , 2017, 18, 1053-1057. | 0.3 | 3 |
| 738 | Idiopathic hypereosinophilic syndrome presenting with severe vasculitis successfully treated with imatinib. <i>World Journal of Clinical Cases</i> , 2016, 4, 328. | 0.3 | 7 |
| 739 | Interlaboratory Development and Validation of a HRM Method Applied to the Detection of JAK2 Exon 12 Mutations in Polycythemia Vera Patients. <i>PLoS ONE</i> , 2010, 5, e8893. | 1.1 | 27 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 740 | JAK2 V617F-Dependent Upregulation of PU.1 Expression in the Peripheral Blood of Myeloproliferative Neoplasm Patients. PLoS ONE, 2011, 6, e22148. | 1.1 | 16 |
| 741 | Acute Progression of BCR-FGFR1 Induced Murine B-Lympho/Myeloproliferative Disorder Suggests Involvement of Lineages at the Pro-B Cell Stage. PLoS ONE, 2012, 7, e38265. | 1.1 | 24 |
| 742 | JAK2 Exon 14 Skipping in Patients with Primary Myelofibrosis: A Minor Splice Variant Modulated by the JAK2-V617F Allele Burden. PLoS ONE, 2015, 10, e0116636. | 1.1 | 8 |
| 743 | Melting Curve Analysis after T Allele Enrichment (MelcaTle) as a Highly Sensitive and Reliable Method for Detecting the JAK2V617F Mutation. PLoS ONE, 2015, 10, e0122003. | 1.1 | 5 |
| 744 | Retrospective Study of High Hemoglobin Levels in 56 Young Adults. Journal of Hematology (Brossard), Tj ETQq0 0 0,rgBT /Overlock 10 T | 0.4 | 3 |
| 745 | The Burden of JAK2V617F Mutated Allele in Turkish Patients With Myeloproliferative Neoplasms. Journal of Clinical Medicine Research, 2015, 7, 161-170. | 0.6 | 11 |
| 746 | The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary Myelofibrosis. Journal of Clinical Medicine Research, 2016, 8, 29-39. | 0.6 | 13 |
| 747 | Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera. Anatolian Journal of Cardiology, 2016, 16, 397-402. | 0.5 | 15 |
| 748 | What Is the Role of JAK2^{V617F} Mutation in Leukemic Transformation of Myeloproliferative Neoplasms?. Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology, 2011, 17, 12-16. | 1.2 | 5 |
| 749 | Acute cerebral infarction in watershed distribution in a patient with hypereosinophilic syndrome. Arquivos De Neuro-Psiquiatria, 2009, 67, 510-512. | 0.3 | 6 |
| 750 | Heteroduplex analysis and pyrosequencing in the diagnostic algorithm of polycythemia vera associated with JAK2 exon 12 mutations. Laboratornaya Sluzhba, 2017, 6, 29. | 0.0 | 6 |
| 751 | All we know about polycythemia vera: literature review and own experience. Oncogematologiya, 2015, 10, 28. | 0.1 | 3 |
| 752 | Assessment of the interlaboratory variability and robustness of <i>JAK2</i>V617F mutation assays: A study involving a consortium of 19 Italian laboratories. Oncotarget, 2017, 8, 32608-32617. | 0.8 | 5 |
| 753 | Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies. Oncotarget, 2011, 2, 485-490. | 0.8 | 44 |
| 758 | Effects of polymorphic DNA genes involved in BER and caspase pathways on the clinical outcome of myeloproliferative neoplasms under treatment with hydroxyurea. Molecular Medicine Reports, 2018, 18, 5243-5255. | 1.1 | 5 |
| 759 | Clinicopathological spectrum of BCR-ABL-Negative myeloproliferative neoplasms with correlation with janus-associated kinase 2 mutation. Indian Journal of Medical and Paediatric Oncology, 2019, 40, 35-40. | 0.1 | 3 |
| 760 | The Current Molecular Site of the Myeloproliferative Neoplasms - TET-ÄtÄ*te with the JAKpot but no LNK so far to Resolve Complexity. Journal of Leukemia (Los Angeles, Calif), 2013, 01, . | 0.1 | 1 |
| 761 | Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms. Turkish Journal of Haematology, 2016, 33, 187-195. | 0.2 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 762 | Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. Turkish Journal of Haematology, 2017, 34, 27-33. | 0.2 | 10 |
| 763 | Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms. Revista Brasileira De Hematologia E Hemoterapia, 2011, 33, 290-296. | 0.7 | 2 |
| 764 | Philadelphia-negative chronic myeloproliferative neoplasms. Revista Brasileira De Hematologia E Hemoterapia, 2012, 34, 140-149. | 0.7 | 14 |
| 765 | Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012. Revista Brasileira De Hematologia E Hemoterapia, 2012, 34, 367-382. | 0.7 | 7 |
| 766 | Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Asian Pacific Journal of Cancer Prevention, 2015, 16, 5013-5018. | 0.5 | 25 |
| 767 | Methylated Alteration of SHP1 Complements Mutation of JAK2 Tyrosine Kinase in Patients with Myeloproliferative Neoplasm. Asian Pacific Journal of Cancer Prevention, 2015, 16, 2219-2225. | 0.5 | 11 |
| 768 | Targeting CD123 in BPDCN: an emerging field. Expert Review of Hematology, 2021, 14, 993-1004. | 1.0 | 8 |
| 769 | Mouse Models of Myeloproliferative Disease Associated with Mutant JAK2 Tyrosine Kinase: Insights into Pathophysiology and Therapy. , 2008, , 1-20. | | 0 |
| 770 | Frequent Reduction or Absence of Detection of the JAK2-Mutated Clone in JAK2V617F-Positive Patients within the First Years of Hydroxyurea Therapy. Blood, 2008, 112, 5225-5225. | 0.6 | 5 |
| 773 | Development of Test System for Detection of V617F Mutation of JAK2 Gene in Patients with Chronic Myeloproliferative Disorders. Nauka Ta Inovacii, 2009, 5, 59-63. | 0.2 | 2 |
| 774 | Essential Thrombocythemia (ET). , 2010, , 15-50. | | 0 |
| 776 | Polycythemia Vera (PV). , 2010, , 51-79. | | 0 |
| 777 | Primary Myelofibrosis (PMF) [Previously Chronic Idiopathic Myelofibrosid (CIMF), Myelofibrosis with Myeloid Metaplasia (MMM), Agnogenic Myeloid Metaplasia (AMM)]. , 2010, , 81-116. | | 0 |
| 778 | The role of FasR/FasL system in pathogenesis of myeloproliferative neoplasms. Archives of Biological Sciences, 2010, 62, 223-230. | 0.2 | 1 |
| 780 | Detection of V617F mutation of gene jak2 at patients with chronic myeloproliferative neoplasms. Biopolymers and Cell, 2010, 26, 214-217. | 0.1 | 2 |
| 781 | Acute Panmyelosis with Myelofibrosis: An Unusual Cause of Pancytopenia. Medical Journal of the University of Toronto, 2010, 87, . | 0.0 | 0 |
| 782 | Pathogenesis, Diagnosis, Classification, and Management of Systemic Mastocytosis. , 2011, , 205-221. | | 0 |
| 783 | Molecular Diagnostic Pathology. , 2011, , 489-513. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 784 | Bone marrow trephine in some hematological and non-hematological disorders. <i>Annals of the College of Medicine Mosul</i> , 2010, 36, 63-71. | 0.0 | 1 |
| 785 | HÄmatologische und immunologische Krankheiten. , 2011, , 217-245. | | 0 |
| 786 | Myeloproliferative Neoplasms. , 2011, , 698-732. | | 2 |
| 790 | Atypical chronic myeloid leukemia (aCML). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2011, , . | 0.1 | 0 |
| 792 | Critical Issues About the Diagnosis of MPNs: Bone Marrow Histopathology. , 2012, , 19-35. | | 0 |
| 793 | Myeloproliferative and "Overlap" Myelodysplastic/Myeloproliferative Neoplasms. , 2012, , 479-522. | | 0 |
| 794 | 8p11 myeloproliferative syndrome (EMS, eight p11 myeloproliferative syndrome). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2012, , . | 0.1 | 0 |
| 795 | Abnormal Megakaryopoiesis in Patients With A JAK2 Exon 12 Mutation May Be A Non-Cell-Autonomous Phenomenon. <i>Journal of Bone Marrow Research</i> , 2013, 01, . | 0.2 | 0 |
| 796 | Diagnstico y tratamiento de la trombocitemia esencial en la edad peditrica. , 2013, , 27-33. | | 0 |
| 798 | TET2 Mutations in Ph-Negative-Myeloproliferative Neoplasms: Identification of Three Novel Mutations and Relationship with Clinical and Laboratory Findings. <i>Open Journal of Blood Diseases</i> , 2013, 03, 79-84. | 0.1 | 0 |
| 799 | A Personalized Molecular Pathogenesis of MDS. , 2013, , 97-109. | | 0 |
| 800 | Determining level of endogenous serum erythropoietin for differential diagnosis of polycythemia vera and symptomatic polycythemia. <i>Medicni Perspektivi</i> , 2013, 18, 66-73. | 0.1 | 0 |
| 802 | Molecular Diagnosis of Cancer. , 2014, , 249-346. | | 1 |
| 804 | Management of Polycythemia Vera and Essential Thrombocythemia. <i>Korean Journal of Medicine</i> , 2014, 86, 26. | 0.1 | 0 |
| 805 | The Importance of Identification of M-BCRABL Oncogene and JAK2 ^{V617F} Mutation in Myeloproliferative Neoplasms. <i>Acta Marisensis - Seria Medica</i> , 2014, 60, 44-48. | 0.3 | 0 |
| 806 | Budd-Chiari Syndrome in a Patient with JAK2V617F and Factor V G1691A Mutations. <i>West Indian Medical Journal</i> , 2014, 63, 528-31. | 0.4 | 3 |
| 807 | Myeloproliferative Neoplasms " Molecular Biology and Potential Targets for Intervention. , 2014, , 62-102. | | 0 |
| 808 | Aid to Enteral Feeding in Critical Care: Algorithm. , 2015, , 1393-1412. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 809 | Frequency and Clinicohematologic Characteristics of MPLW515 Mutations in Patients with Myeloproliferative Neoplasms. <i>Laboratory Medicine Online</i> , 2015, 5, 1. | 0.0 | 1 |
| 810 | Bone Marrow Features and Natural History of BCR/ABL-Positive Thrombocythemia and Chronic Myeloid Leukemia Compared to BCR/ABL-Negative Thrombocythemia in Essential Thrombocythemia and Polycythemia Vera. <i>Journal of Hematology & Thromboembolic Diseases</i> , 2015, 03, . | 0.1 | 0 |
| 811 | Pulmonary Hypertension in Chronic Myeloproliferative Disorders. <i>Advances in Pulmonary Hypertension</i> , 2015, 14, 150-154. | 0.1 | 0 |
| 812 | Myeloproliferative Neoplasm with Extensive Myeloid Metaplasia: A Diagnostic Dilemma. <i>Journal of Postgraduate Medicine Education and Research</i> , 2015, 49, 148-154. | 0.1 | 0 |
| 814 | VEGF, D-dimer and Coagulation Activation Markers in Indonesian Patients with Polycythemia Vera and Essential Thrombocythemia and Their Relation with Recurrence of Thrombosis. <i>International Archive of Medicine</i> , 0, , . | 1.2 | 0 |
| 818 | The Emergence of Multiple Myeloma in a Patient with Essential Thrombocythemia: A Case Report. <i>Journal of Hematology and Blood Disorders</i> , 2015, 1, . | 0.1 | 2 |
| 820 | Developing method for allelic somatic mutations burden of Janus kinase 2 (V617F JAK2) detection in pools of venous blood samples. <i>Laboratornaya Sluzhba</i> , 2016, 5, 19. | 0.0 | 3 |
| 822 | Association Between Soluble CD40L with Thrombosis Occurrence and JAK2 V617F Mutation in Essential Thrombocythemia. <i>American Journal of Internal Medicine</i> , 2016, 4, 60. | 0.1 | 0 |
| 823 | Informative Value of Combination of Molecular Genetic and Cytogenetic Diagnostic Methods in Myelofibrosis. <i>Lviv Clinical Bulletin</i> , 2016, 1, 22-25. | 0.1 | 0 |
| 824 | Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis. <i>Turkish Journal of Haematology</i> , 2016, 33, 94-101. | 0.2 | 5 |
| 825 | Estimate of JAK 2 V617F Mutation and Activity of Catalase Enzyme in Myeloproliferative Neoplasm. <i>Journal of Al-Nahrain University-Science</i> , 2016, 19, 1-8. | 0.1 | 0 |
| 826 | On the issue of validation of the method for somatic mutations determining in Janus kinase-2 (JAK2V617F), calreticulin (CALR) and receptor of thrombopoietin (MPL) genes in the dry blood drops. <i>Laboratornaya Sluzhba</i> , 2017, 6, 178. | 0.0 | 0 |
| 827 | THROMBOTIC AND BLEEDING RISK FACTORS IN ESSENTIAL THROMBOCYTHEMIA. <i>Oncogematologiya</i> , 2017, 12, 30-38. | 0.1 | 0 |
| 828 | A Case of Myeloid Neoplasm with a PDGFRB Rearrangement and Eosinophilia. <i>Korean Journal of Medicine</i> , 2017, 92, 79-83. | 0.1 | 0 |
| 829 | TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms. <i>Turkish Journal of Haematology</i> , 2017, 34, 174-178. | 0.2 | 2 |
| 830 | Molecular Genetic Markers and Clinical Characteristics of Essential Thrombocythemia. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2017, 10, 402-408. | 0.1 | 1 |
| 831 | Overview of Myeloproliferative Neoplasms. , 2018, , 458-461. | | 0 |
| 832 | Myeloproliferative Neoplasm, Unclassifiable. , 2018, , 512-517. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 833 | Overview and Classification of Myeloid Neoplasms. , 2018, , 450-455. | | 0 |
| 834 | The Role of Advanced Practitioners in Optimizing Clinical Management and Support of Patients With Polycythemia Vera. Journal of the Advanced Practitioner in Oncology, 2018, 9, . | 0.2 | 0 |
| 836 | Mastocytosis in practice of a family doctors. Shidnoevropejskij Zurnal Vnutrisnoi Ta Simejnoi Medicini, 2018, 2018, 22-27. | 0.0 | 1 |
| 837 | The association of mean platelet volume and platecrit and bone marrow fibrosis in patients with essential thrombocythemia: A cohort study. Journal of Surgery and Medicine, 0, , . | 0.0 | 2 |
| 838 | Successful treatment of pulmonary embolism in a patient with polycythemia vera by rheolytic thrombectomy. Journal of Cardiovascular and Thoracic Research, 2019, 11, 325-327. | 0.3 | 1 |
| 840 | Clinical Spectrum of Primary Polycythaemia and Its Complications - Experience from a Single Center in Karnataka. Journal of Evolution of Medical and Dental Sciences, 2020, 9, 2461-2465. | 0.1 | 0 |
| 841 | Hematolojik malignitelerde konvansiyonel sitogenetik, molekül sitogenetik ve molekül genetik sonu lar de erlendirilmesi. Sleyman Demirel Aceniversitesi Tıp Fakültesi Dergisi, 0, , . | 0.0 | 1 |
| 842 | Philadelphia-negative myeloproliferative neoplasms: From origins to new perspectives. International Review of Cell and Molecular Biology, 2021, 365, ix-xx. | 1.6 | 0 |
| 843 | Diagnosis and Treatment of Clonal Myeloproliferative Neoplasms with Eosinophilia. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2020, 13, 161-169. | 0.1 | 2 |
| 844 | Identification of <i>JAK2</i> (V617F) Mutation in Myeloproliferative Neoplasms by Using Allele Specific Polymerase Chain Reaction (AS-PCR). American Journal of Molecular Biology, 2020, 10, 273-282. | 0.1 | 1 |
| 845 | Incidence in Ph-Negative Myeloproliferative Neoplasms in Armenia from 2005 to 2019. Open Journal of Epidemiology, 2020, 10, 355-368. | 0.2 | 0 |
| 846 | Screening for precapillary pulmonary hypertension in chronic myeloproliferative disorders: the role of N-terminal pro-B-type natriuretic peptide and vascular endothelial growth factor " a pilot study. Archives of Medical Science, 2020, 17, 1628-1635. | 0.4 | 0 |
| 847 | Platelet-derived growth factors and their receptors in normal and malignant hematopoiesis. American Journal of Blood Research, 2012, 2, 44-56. | 0.6 | 52 |
| 848 | The simultaneous occurrence of multiple myeloma and JAK2 positive myeloproliferative neoplasms - Report on two cases. Journal of Medicine and Life, 2015, 8, 55-61. | 0.4 | 1 |
| 849 | Diagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary Roundtable. American Health and Drug Benefits, 2014, 7, S36-47. | 0.5 | 10 |
| 850 | The impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia. Journal of Medicine and Life, 2015, 8, 502-8. | 0.4 | 14 |
| 851 | Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera. American Health and Drug Benefits, 2015, 8, 75-9. | 0.5 | 27 |
| 852 | Molecular Diagnostics with Laboratory Finding in Patients with Myeloproliferative Neoplasms. Iranian Journal of Public Health, 2017, 46, 1598-1600. | 0.3 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 853 | The Role of Advanced Practitioners in Optimizing Clinical Management and Support of Patients With Polycythemia Vera. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018, 9, 56-66. | 0.2 | 0 |
| 858 | rs779805 Von Hippel-Lindau Gene Polymorphism Induced/Related Polycythemia Entity, Clinical Features, Cancer Association, and Familial Characteristics. <i>Pathology and Oncology Research</i> , 2021, 27, 1609987. | 0.9 | 2 |
| 859 | Philadelphia-negative myeloproliferative neoplasms: From origins to new perspectives. <i>International Review of Cell and Molecular Biology</i> , 2022, 366, ix-xx. | 1.6 | 0 |
| 860 | Clinical features of mastocytosis at pediatric patients. <i>Vestnik Dermatologii i Venerologii</i> , 2017, 93, 12-20. | 0.2 | 2 |
| 861 | Cerebrovascular Accident in a Patient with Polycythemia: a Case Report. <i>Rational Pharmacotherapy in Cardiology</i> , 2022, 18, 79-84. | 0.3 | 0 |
| 862 | Case Report: Free-Floating Intracoronary Thrombus: Who Is the Convict?. <i>Frontiers in Oncology</i> , 2022, 12, 825711. | 1.3 | 1 |
| 863 | JAK2V617F Is a Risk Factor for TIA/Stroke in Young Patients. <i>Thrombosis and Haemostasis</i> , 2022, , . | 1.8 | 1 |
| 864 | Evaluation of Thromboembolism According to Mutation Status in Patients with Essential Thrombocythosis; Single-Center Experience. <i>Ankara EĀYitim Ve AraĀYtĀ±rma Hastanesi TĀ±p Dergisi</i> , 2022, 54, 429-433. | 0.1 | 0 |
| 865 | Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study. <i>International Journal of Hematology</i> , 2022, 116, 215-227. | 0.7 | 8 |
| 866 | TGF-Ī ² signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche. <i>Journal of Clinical Investigation</i> , 2022, 132, . | 3.9 | 10 |
| 867 | Bone marrow. , 0, , 813-942. | | 0 |
| 868 | Myeloproliferative neoplasms. , 0, , 141-154. | | 0 |
| 871 | Myeloid neoplasm with the abnormality of PDGFRB gene secondary interstitial pneumonia: A case report. <i>Journal of Central South University (Medical Sciences)</i> , 2020, 45, 345-348. | 0.1 | 0 |
| 877 | Aberrant Activation-Induced Cytidine Deaminase Gene Expression Links BCR/ABL1-Negative Classical Myeloproliferative Neoplasms. <i>Haseki Tip Bulteni</i> , 2022, 60, 228-233. | 0.2 | 0 |
| 878 | Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis â€“ an option beyond ruxolitinib. <i>Expert Review of Hematology</i> , 2022, 15, 583-595. | 1.0 | 4 |
| 879 | The differences of hemogram, myelogram, and driver gene mutations in classic myeloproliferative neoplasms. <i>Blood Cells, Molecules, and Diseases</i> , 2022, , 102698. | 0.6 | 0 |
| 880 | Ká³¼T QUá²c Āĳá»ĒU TRá»Š Tá²N CĀ”NG á»ž Bá»†NH NHĀ,N TĀ,NG TIá»,U Cá² U TIĀŠN PHĀĪ Tá²l VIá»†N HUYá²³¼T HÁ»ĒC TRUYá»ĒN Nam, 2022, 517, . | 0.0 | 0 |
| 881 | Retinal oxygen saturation in monoclonal gammopathies patients: AĀpilot study. <i>Acta Ophthalmologica</i> , 0, , . | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 883 | Juvenile Myelomonocytic Leukemia in a Child: A Case Report of Palliative Chemotherapy and Literature Review Applied to Limited Resources Centers. <i>Case Reports in Hematology</i> , 2022, 2022, 1-7. | 0.3 | 0 |
| 884 | Non-Classic Myeloproliferative Neoplasms: Are We Really Aware of These Rare Diseases in Daily Practice?. <i>European Medical Journal (Chelmsford, England)</i> , 0, , 113-120. | 3.0 | 0 |
| 885 | Development of multiple myeloma after 15 years of treatment for polycythemia vera and successful treatment using bortezomib: A case report. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, . | 0.2 | 0 |
| 887 | Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer. <i>Pharmacological Reviews</i> , 2023, 75, 35-61. | 7.1 | 12 |
| 888 | Bilateral adrenal and pulmonary haemorrhages as an initial presentation of polycythaemia vera. <i>BMJ Case Reports</i> , 2022, 15, e252013. | 0.2 | 0 |
| 889 | Novel ATM Gene c.5644 C > T (p.Arg1882*) Variant Detected in a Patient with Pancreatic Adenocarcinoma and Two Primary Non-Small Cell Lung Adenocarcinomas: A Case Report. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 115. | 1.0 | 0 |
| 890 | Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities. <i>Leukemia</i> , 2023, 37, 843-853. | 3.3 | 4 |
| 891 | Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases. <i>Frontiers in Oncology</i> , 0, 13, . | 1.3 | 1 |
| 892 | Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology. <i>Cells</i> , 2023, 12, 946. | 1.8 | 2 |
| 893 | Syndrome confusionnel et maladie de Vaquez. <i>Information Psychiatrique</i> , 2011, Volume 87, 515-517. | 0.1 | 0 |
| 904 | Molecular testing in myeloproliferative neoplasms. , 2024, , 569-587. | | 1 |